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ABSTRACT 
 Ghrelin is a 28-amino acid peptide predominantly produced in the stomach and 
secreted into the circulation. Ghrelin is found in plasma and tissues in two major forms 
of n-octanoyl-modified at its N-terminal third serine residue and des-acyl ghrelin. The n-
octanoyl group of ghrelin is essential for its growth hormone (GH)-releasing activity and 
appetite regulation mediated through growth hormone secretagogue receptor (GHS-R). 
We demonstrated that both ghrelin and des-acyl ghrelin evoke vasodilatation at 
remarkably low concentrations compared to acetylcholine (ACh) in phenylephrine (PE)-
constricted perfused rat mesenteric vascular bed (MVB). This was abolished in 
endothelium-denuded preparations and in endothelium-intact preparations exposed to 
either a calcium-activated potassium channel (KCa) blocker or a depolarizing stimulus. 
While KATP channel blockade, nitric oxide synthase and cyclooxygenase inhibition had 
no effect, the responses were abolished in the presence of combinations of apamin and 
charybdotoxin, apamin and TRAM-34, and ouabain and Ba2+. The GHS-R antagonist, 
[D-Lys3]-GHRP-6, per se evoked vasodilatation. Inclusion of L-756867, a peptide 
antagonist of classical GHS-R, failed to evoke any vasodilator response or to affect 
vasodilatation evoked by ghrelin. Both non-peptide agonists of GHS-R, L-166446 and 
L-163255, demonstrated concentration-dependent decreases in perfusion pressure. All 
short peptides encompassing the first 20, 16, 10, 6, 4, and 3 residues of des-acyl ghrelin 
were able to evoke vasodilator responses to the same extent as des-acyl ghrelin. 
However, vasodilatation to single amino acids, L-serine and glycine, were significantly 
attenuated. Streptozotocin (STZ)-induced diabetes increased plasma ghrelin 
concentration. Diabetes for 4-weeks did not cause any significant reduction in ghrelin-
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evoked vasodilatation, whereas 8-weeks diabetes significantly reduced ghrelin-evoked 
vasodilatation. In contrast to ghrelin, there was a duration-dependent fall in vasodilator 
response to ACh from 4- to 8-weeks diabetes. These data suggest that the vasodilatation 
evoked by ghrelin is mediated by endothelium-dependent hyperpolarization (EDHF) by 
mechanism(s) that are independent of classical GHS-R activation. In addition, EDHF-
dependent ghrelin-evoked vasodilator responses may not be affected, at least in the early 
stages of STZ diabetes, whereas the responses to ACh, predominantly mediated through 
nitric oxide, are progressively diminished right from the early stages of endothelial 
dysfunction in STZ diabetic rats.     
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1. INTRODUCTION 
1.1. Endothelium and Regulation of Vascular Tone 
 The entire blood vessel consists of a number of layers of different cells and 
tissues, each performing different functions in different arteries, capillaries, and veins. 
Large arteries are typified by an outermost layer of smaller arteriols and venules 
(adventitia) that provide nutrient, and connective tissue components to provide support 
and anchorage. The middle layer (media) is composed mostly of smooth muscle cells 
(that provide vascular tone) with a smaller number of fibroblasts. The innermost layer, 
the intima, which interfaces directly with the blood, is composed entirely of endothelial 
cells (EC) sitting on a basement membrane that separates it from the media. The EC do 
not form a passive layer between the blood and the rest of the blood vessel, but quite the 
opposite, they perform vital functions in haemostasis, in managing tissue fluid and 
leukocyte movement into the vessel wall, and in regulating vascular tone (Esper et al., 
2006). 
 
The endothelium plays a primary role in the local control of vascular tone by 
releasing contracting and relaxing factors both under basal conditions and when 
activated by neurotransmitters, hormones, autocoids, or physical stimuli (Thomas et al., 
1993; Taddei et al., 2006). Endothelium-derived contracting factors are partly produced 
by the cyclooxygenase (COX) pathway from arachidonic acid (AA). The products of 
COX mediating the contractions are thromboxane A2 (TXA2) and endoperoxides, such 
as prostaglandin H2 (PGH2), which activate endoperoxide-thromboxane A2  receptors 
(TP receptors) on vascular smooth muscle cells (VSMC) (Vanhoutte, 1993; 1996; 2001). 
2 
The COX pathway is also a source of superoxide anions, which can mediate 
endothelium-dependent contractions either by the breakdown of nitric oxide (NO) or by 
direct effects on VSMC. EC also produce the 21-amino acid peptide endothelin-1 (ET-
1). Among the three forms of this peptide, ET-1, ET-2, and ET-3, ECs appear to produce 
exclusively ET-1 (Luscher and Vanhoutte, 1990). The peptide ET-1 is a potent 
vasoconstrictor that under normal conditions circulates at low levels. The renin-
angiotensin system (RAS) is another cascade of enzymatic reactions that ends in the 
production of a potent vasoconstrictor, angiotensin II (Ang II). Renin, produced by the 
kidney, acts on angiotensinogen, produced by the liver, degrading it to angiotensin I 
(Ang I), which in turn is acted on by circulating or tissue angiotensin converting enzyme 
(ACE) and hydrolyzed to Ang II. The EC release Ang II, which through the activation of 
Ang I receptors causes contraction of blood vessels (Esper et al., 2006). 
 
Endothelium-dependent relaxation, however, is mediated through three different 
mechanisms: endothelium-derived relaxing factor (EDRF, NO), prostacyclin (PGI2), and 
an as yet unidentified endothelium-derived hyperpolarizing factor (EDHF) (He, 2005). 
The contribution of these three vasodilators to vascular relaxation varies among different 
vessels and vascular beds (Shimokawa et al., 1996). It has been reported that the 
contribution of EDHF to endothelium-dependent vasodilatation increases as the vessel 
size decreases (Tomioka et al., 1999; Fitzgerald et al., 2005).  
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1.1.1. Endothelium-Derived Relaxing Factor (NO) 
Furchgott and Zawadzki (1980) postulated that upon stimulation by acetylcholine 
(ACh), EC release a diffusible vasodilator substance, which relaxes the blood vessels. 
Ignarro and co-workers (1987) clarified the chemical identity of EDRF as NO. NO is 
formed in EC from the amino acid L-arginine by oxidation of its guanidine-nitrogen 
terminal by the enzyme endothelial NO synthase (eNOS), which requires calmodulin, 
calcium (Ca2+), nicotinamide adenine dinucleotide phosphate (NADPH), and 
tetrahydrobiopterine (BH4) (He, 2005). Several isoforms of the enzyme occur not only in 
EC, but also in platelets, macrophages, VSMC, and in the brain (Radomski et al., 1990). 
It appears that the endothelial enzyme is a constitutive Ca2+-dependent enzyme and 
produces picomoles of NO, whereas the enzyme in VSMC is an inducible Ca2+-
independent enzyme, which produces nanomoles of NO under stimulation by endotoxin, 
interleukin-1, and tumor necrosis factor (Luscher and Tanner, 1993). In the vascular 
system, the endothelium-derived NO diffuses out of EC and a portion of it arrives at the 
underlying smooth muscle cell layer (Rubanyi et al., 1986). It is generally conceded that 
vasodilatation to NO is associated with stimulating the soluble enzyme guanylyl cyclase 
(sGC), and in turn, the formation of cyclic 3’, 5’-guanosine monophosphate (cGMP) in 
smooth muscle cells, which results in the activation of a family of serine/thereonine 
protein kinases, cGMP-dependent protein kinase (PKG) (Lincoln et al., 2001). 
Intracellular events downstream activation of PKG, however, are still much debated.  
 
 
4 
There appears to be three major pathways regulated by NO/cGMP/PKG 
signaling that induce relaxation in smooth muscle cells: (1) Decrease in intracellular free 
Ca2+ concentrations ([Ca2+]i), (2) Ca2+ desensitization, and (3) Thin filament regulation. 
It is likely that no single pathway acts exclusively or independently in any one type of 
smooth muscle cell. However, the relative importance of the various pathways leading to 
cGMP-induced relaxation is likely to be different in cells from large arteries compared 
to those from microvessels (Lincoln et al., 2001). A comprehensive picture 
demonstrating all the proposed mechanisms of NO/cGMP/PKG-mediated relaxation of 
smooth muscle cells is shown in Figure 1.  
 
(1) Decrease in [Ca2+]i. The first mechanism proposed for cGMP-dependent 
relaxation of smooth muscle cells was the reduction of [Ca2+]i (Johnson and Lincoln, 
1985). So far, as increases in Ca2+ were required for myosin light chain (MLC) 
phosphorylation and contraction, the reduction in cytosolic free Ca2+ by cGMP was seen 
primarily as a reversal of the contractile mechanism. Several sites of action have been 
proposed to account for NO/cGMP/PKG-mediated reduction of cytosolic Ca2+ 
(Hofmann et al., 2000; Lincoln et al., 2001):  
(a) PKG has been demonstrated to directly inhibit voltage-gated Ca2+ channels 
(Hofmann et al., 2000). 
(b) Phosphorylation of sarcoplasmic reticulum (SR) protein, phospholamban, has been 
suggested as another mechanism through which PKG contributes to the influx of Ca2+ 
into the SR (SR Ca2+ loading) through Ca2+-ATPase pump and thus decreased [Ca2+]i 
and relaxation (Mundian-Weilenmann et al., 2000). 
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(c) cGMP/PKG is involved in the regulation of the inositol 1, 4, 5-triphosphate (IP3) 
receptor. Previous studies demonstrated that the smooth muscle IP3 receptor (IP3R) is 
phosphorylated by PKG (Haug et al., 1999). PKG-dependent phosphorylation of IP3R 
decreases Ca2+ release from the SR, and this effect is dependent on the targeting of PKG 
to the SR (Schlossman et al., 2000). A targeting protein for PKG, termed IP3 receptor-
associated PKG-I substrate (IRAG), has been characterized and shown to be necessary 
for IP3R phosphorylation (Lincoln et al., 2001).  
(d) Several types of potassium (K+) channels have been shown to be involved in 
NO/PKG-mediated relaxation. K+ channel activation stabilizes the cell by increasing 
efflux of K+ ions, leading to hyperpolarization, and thus decreased cell excitability (He, 
2005; Ghatta et al., 2006). NO/cGMP/PKG has been shown to activate adenosine 
triphosphate (ATP)-sensitive K+ (KATP) channels in rat mesenteric arteries as well as in 
guinea pig coronary arteries (Katakam et al., 1999; Triggle et al., 2004). In addition, NO 
also relaxes various blood vessels by increasing the gating of big conductance calcium-
activated potassium (BKCa) channels either directly or via PKG (Mistry and Garland, 
1998; Lincoln et al., 2001). It has been reported that PKG regulates the phosphorylation 
of the BKCa channels by acting as a direct catalyst for phosphorylation (Fukao et al., 
1999). Increased BKCa activity also appears to arise from PKG-mediated increased 
activity of spontaneous transient outward currents (STOCs) produced by small bursts of 
Ca2+ released from the superficial SR through ryanodine receptors (RYR) (Nelson et al., 
1995). Increased BKCa channel activity hyperpolarizes the smooth muscle membrane and 
reduces [Ca2+]i through inhibition of voltage-gated Ca2+  channels. As a result, a decrease 
in global Ca2+ occurs, leading to the dephosphorylation of MLC and relaxation (Lincoln 
et al., 2001). 
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 (2) Ca2+ desensitization. Ca2+ sensitization is the term used to describe the 
increase in contractile activity produced by G protein (guanine nucleotide binding 
protein)-coupled agonists. MLC phosphorylation at serine-19 is necessary for actin 
activation of myosin ATPase, and subsequent cross-bridge cycling and contraction. Two 
key enzymes involved in the control of MLC phosphorylation are MLC kinase (MLCK), 
a Ca2+/calmodulin-activated kinase, and a MLC phosphatase (MLCP), a 
serine/thereonine protein phosphatase type I. With respect to the regulation of MLCK, 
there has been no firm evidence that PKG-dependent phosphorylation of MLCK inhibits 
its activity (Van Riper et al., 1997). Most of the recent work suggests that PKG activates 
MLCP, thereby inhibiting MLC phosphorylation and contraction (Lincoln et al., 2001). 
An important component of the Ca2+ sensitization mechanism is the Rho-Rho kinase-
dependent inhibition of MLCP following agonist stimulation of contraction (Gong et al., 
1996). PKG apparently opposes Rho kinase-induced inhibition of the phosphatase by 
phosphorylating the myosin-binding subunit (MBS) of MLCP, thus activating the 
catalytic subunit of the phosphatase (Surks et al., 1999; Torrecillas et al., 2000). These 
studies have also shown that PKG is targeted to the MBS, thus placing it in an ideal 
location to activate MLCP. There are further reports that suggest that cGMP/PKG may 
interfere with the Rho-dependent activation of Rho kinase, possibly through the 
phosphorylation of Rho (Sauzeau et al., 2000).    
 
 
 
 
7 
(3) Thin-filament regulation. The role of the thin filament in the regulation of 
smooth muscle cell contraction has been somewhat controversial. Thin filament binding 
proteins regulate and contribute to the contractile activity of the cell, but there have been 
few reports regarding the role of second messenger regulation of thin filament protein 
function. More recently, the thin filament/actin binding protein, 20-KDa heat shock-
related protein (HSP20), gained some attention as a potential target for PKG action 
(Yamboliev et al., 2000). HSP20 was reported to be a specific target for PKG-dependent 
phosphorylation. Phosphorylation of HSP20 serine-16 by PKG is associated with 
relaxation of smooth muscle. 
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1.1.2. Prostacyclin (PGI2)       
 PGI2 was the first defined relaxing factor derived from endothelium (Moncada et 
al., 1976). When activated by stimuli, the enzyme phospholipase A2 (PLA2) in EC 
converts membrane phospholipids to AA that is subsequently metabolized to PGI2 by 
the enzyme COX. The vasodilatation induced by PGI2 is mediated by the rise of cyclic 
3’, 5’-adenosine monophosphate (cAMP) through increased activity of adenylyl cyclase 
(AC), and the subsequent activation of cAMP-dependent protein kinase (PKA) in 
VSMC (Luscher and Tanner, 1993; Hecker, 2000). Similar to NO/cGMP/PKG, 
activation of PGI2/cAMP/PKA pathway also leads to the reduction of [Ca2+]i, decreased 
sensitivity of the contractile apparatus to Ca2+, and regulation of the thin filament  
(Luscher and Tanner, 1993; Hecker, 2000; Lincoln et al., 2001; Pfitzer, 2001; He, 2005). 
PKA has been shown to phosphorylate, and thus directly inhibit voltage-gated Ca2+ 
channels. The involvement of different types of K+ channels has also been demonstrated 
in the PGI2-mediated hyperpolarization in different vascular beds (He, 2005). PGI2 has 
been shown to activate BKCa channels in three different ways: (1) Direct channel 
activation through its Gs-coupled receptor, which is cAMP-independent; (2) 
Phosphorylation and activation of the channel by PKA; and (3) Phosphorylation of RYR 
channels on the SR, and therefore increased small bursts of Ca2+ near BKCa channels on 
the plasma membrane (Schubert et al., 1996; Lincoln et al., 2001; Ghatta et al., 2006).  
In addition to the activation of BKCa channels, PGI2 has been shown to activate smooth 
muscle cell KATP and inward-rectifier K+ (Kir) channels through the secondary rise in 
cAMP/PKA after binding to its corresponding cell surface receptor (Li et al., 1997).  
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 Similar to cGMP/PKG, it is well established that cAMP/PKA also decreases 
Ca2+ sensitivity of contraction in both intact and permeabilized smooth muscles (Pfitzer, 
2001). In vitro, PKA was shown to phosphorylate MLC kinase (MLCK) at two sites, site 
A and B, located carboxy terminal to the calmodulin binding domain. Phosphorylation 
of site A, but not site B, decreased the affinity of MLCK for the Ca2+/calmodulin 
complex. However, agonists that elevated cAMP in vivo had negligible effects on the 
phosphorylation of site A and Ca2+ activation of MLCK (Pfitzer, 2001). This suggested 
that cAMP may desensitize smooth muscle by an alternative, yet not defined, 
mechanism. Activity of MLCP is increased by cGMP/PKG, and perhaps also 
cAMP/PKA (Pfitzer, 2001). PKA has also been involved in the regulation of thin 
filaments; PKA activation, like PKG, also phosphorylates the thin filament binding 
protein, HSP20 (Brophy et al., 1999). Phosphorylation of HSP20 is associated with 
relaxation of VSMC (Lincoln et al., 2001).  
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1.1.3. Endothelium-Derived Hyperpolarizing Factor (EDHF) 
Endothelium-dependent vasodilatation to different vasodilator agonists in various 
isolated blood vessels and vascular preparations is only partially inhibited, or not 
changed, by a combination of a NOS inhibitor and a COX inhibitor (Luscher and 
Tanner, 1993). EC, therefore, appear to release another relaxing factor distinct from NO 
and PGI2. Endothelium-derived hyperpolarizing factor (EDHF) is defined as the non-
NO/PGI2 endothelium-derived vasodilator factor that mediates VSMC hyperpolarization 
and therefore relaxation (Ge et al., 2000; Triggle et al., 2004). It has been suggested that, 
in most instances, the agonist (eg. ACh)-stimulation of EC increases [Ca2+]i, which in 
turn results in the extrusion of K+ ions through both small- and intermediate-
conductance calcium-activated potassium (SKCa and IKCa, respectively) channels. 
Increased K+ concentration in the myo-endothelial space activates Na+/K+-ATPase pump 
and inward rectifying K+ (Kir) channels on VSMC, leading to hyperpolarization and 
relaxation of VSMC (Triggle et al., 2004). Thus, the hypothesis is that it is the apamin-
sensitive SKCa and the charybdotoxin (ChTX)-sensitive IKCa channels on the EC that 
regulate EDHF release, and the ouabain-sensitive Na+/K+-ATPase and Ba2+-sensitive Kir 
channels on the VSMC that mediate vasodilatation of EDHF (Campbell et al., 1996; 
Mombouli and Vanhoutte, 1997; Edwards et al., 1998; Triggle et al., 2004). In most 
cases, an EDHF-mediated vasodilatation lacks sensitivity to either BKCa blocker, 
iberiotoxin, or KATP channel blocker, glibenclamide (Edwards et al., 1998; Hecker, 
2000). 
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However, the identity or chemical nature of EDHF is still under much 
discussion. It is still not clear if EDHF is K+ ions themselves, which accumulate in myo-
endothelial space upon stimulation of SKCa and IKCa, or if it is just the agonist-induced 
hyperpolarization that is propagated from EC to the underlying VSMC via 
myoendothelial gap junctions. It may also be a substance or molecule that is released 
from EC upon their agonist stimulation into myoendothelial space and activates its 
receptors on EC and VSMC, leading to their hyperpolarization and thus relaxation. The 
potential role of K+ ions as EDHF was first suggested by Edwards et al. (1998) who 
reported that in the rat hepatic artery, ACh mediated an increase in K+ concentration, as 
measured by a K+-sensitive microelectrode. They also recorded membrane potential with 
sharp glass microelectrodes and illustrated that ACh can hyperpolarize both VSMC and 
EC. An increase in extracellular K+ concentration by 5 mmol/L mimicked the effects of 
ACh and comparable data was reported for the rat mesenteric artery preparation. Hence 
the data from Edwards et al. (1998) provided strong support that small changes in 
extracellular K+, which were already known to cause VSMC relaxation, may represent 
the putative EDHF. However, up to now, the proposed idea has not been universally 
accepted (Ding and Trrigle, 2000). Moreover, Hecker (2000) also represented that an 
increase in myo-endothelial K+ ion level to an extent of double its normal concentration 
is unlikely to be effective in thick-walled arteries such as coronary arteries. It is 
noteworthy to mention that, however, the identity of EDHF may differ in different 
vasculatures and vascular beds (He, 2005). 
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Myo-endothelial gap junctions have been reported to be able, via intercellular 
channels, to provide a pathway for the passage of small water-soluble molecules (<1000 
Da), including cAMP, cGMP, IP3, as well as inorganic ions including Ca2+ , but not 
proteins, to pass between adjacent connecting cells (Kumar and Gilula, 1996). Electrical 
coupling between EC and VSMC should also be considered, especially for the 
microcirculation, in which the relative contribution of EDHF to endothelium-dependent 
vasodilatation appears to be much more prominent than in conduit arteries (Mombouli 
and Vanhoutte, 1997; Hecker, 2000).  
  
In addition to the above, there are several candidate molecules that, to varying 
extents, fulfill some of the criteria that would be expected of an EDHF and a number of 
these are enzymatically derived from AA (Triggle et al., 2004): (1) Epoxyeicosatrienoic 
acids, EETs. EETs are generated via an epoxygenase from AA and are attractive 
candidates for EDHF in a number of vascular beds, notably in the coronary vascular bed 
(Fleming, 2001). Cytochrome P450 (CYP 450) enzymes can metabolize AA to 
vasoactive substances and the CYP 2J2 isoform, that is expressed in both human EC and 
VSMC, can generate EETs and an accumulation of evidence suggests that these products 
have important physiological and pathophysiological effects in the cardiovascular 
system (Fleming, 2001). Nevertheless, the role of EETs as EDHF has been questioned 
because their action does seem to be primarily mediated via iberiotoxin-sensitive BKCa 
channels and not the apamin- and ChTX-sensitive mechanism that is typical of EDHF 
(McGuire et al., 2001).  
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(2) Isoprostanes. Isoprostanes have been hypothesized by Janssen (2002) to be 
candidate molecules for EDHF. Isoprostanes are generated via the action of PLA2, from 
polyunsaturated fatty acids, such as AA, under circumstances when oxygen free radicals 
are elevated. Isoprostanes, such as thromboxanes, may serve as endothelium-derived 
contracting factors, as well as EDHF, as for instance 8-isoPGE2 is a vasoconstrictor. 
EDHF-mediated responses have been reported to be sensitive to PLA2 inhibitors 
(McGuire et al., 2001; Janssen, 2002).  
  
(3) Anandamide. Anandamide, an endogenous cannabinoid, is another AA 
product via a transacylase and also has been advanced as a possible EDHF in some 
vascular beds (Randal et al., 1996). The main reason for this hypothesis was that the 
EDHF-mediated vasodilatation of the rat mesenteric artery is impaired by the CB1 
cannabinoid receptor antagonist SR-141716A, and that the anandamide-induced 
vasodilatation in this vascular bed is sensitive both to SR-141716A and to membrane 
depolarization through raising K+ concentration (Chataigneau et al., 1998; Randall and 
Kendall, 1998). Subsequent studies in this, as well as in several other vascular 
preparations, have demonstrated, however, that anandamide is a very poor 
hyperpolarizing factor and that its effects on K+ channel activity in VSMC can be clearly 
distinguished from those of EDHF (Chataigneau et al., 1998). It thus seems unlikely that 
anandamide per se is an EDHF.  
  
(4) Hydrogen peroxide (H2O2). H2O2 may be produced in the endothelium from 
superoxide anions via superoxide dismutase (SOD) and in situations where the eNOS 
substrate, L-arginine, or co-factor, tetrahydrobiopreine (BH4), have been depleted, for 
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instance in disease states where there is high oxidative stress (Pannirselvam et al., 2002). 
eNOS can also generate superoxide anions as can CYP and NADPH (Stroes et al., 
1998). Matoba et al. (2000) determined ACh-mediated vasodilatation of small 
mesenteric arteries from eNOS-/- mice and reported that catalase, an enzyme that 
dismutates H2O2 to water and oxygen, inhibited EDHF-mediated hyperpolarization and 
vasodilatation. It must be noted, however, that catalase has been shown to inhibit COX-
dependent 8-iso PGF2α, thus suggesting that H2O2 may not be the final mediator of 
EDHF (Watkins et al., 1999). In addition, H2O2-mediated vasodilatation was shown to 
lack the sensitivity to the combination of apamin and ChTX (Beny and der Weid, 1991). 
 
(5) C-type natriuretic peptide (CNP). It has been recently demonstrated that in 
the rat mesenteric vasculature, the release of CNP accounts for the biological activity of 
EDHF (Chauhan et al., 2003; Sandow and Tare, 2007). EDHF-dependent vasodilatation 
is concomitant with liberation of endothelial CNP. CNP release and EDHF responses are 
profoundly suppressed after endothelial denudation (Chauhan et al., 2003). In addition, 
similar to EDHF, CNP produces VSMC hyperpolarization that is attenuated in the 
presence of high K+ concentration, Gi protein inhibitor pertusis toxin, the G protein-
gated inwardly rectifying K+ channel (GIRK) inhibitor tertiapin, and a combination of 
Ba2+ (Kir channel blocker) plus ouabain (Na+/K+-ATPase inhibitor) (Chauhan et al., 
2003). Responses to both EDHF and CNP are mimicked by the selective natriuretic 
peptide receptor-C (NPR-C) agonist, cANF4-23. Therefore, the data demonstrate that 
ACh-evoked release of endothelial CNP activates NPR-C on VSMC that via Gi coupling 
promotes Ba2+/ouabain-sensitive hyperpolarization (Chauhan et al., 2003). However, in 
addition to the information above, key data supporting the hypothesis that CNP is EDHF 
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are still required. In the rat mesenteric artery, a crucial investigation is whether the 
combination of ChTX-TRAM-34 and apamin prevents CNP release from the 
endothelium, since blockade of the EDHF response by these agents is a defining feature 
of EDHF in this vessel (Grane et al., 2003; Sandow and Tare, 2007).  
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1.2. ENDOTHELIAL DYSFUNCTION AND CARDIOVASCULAR 
DISEASE  
 Because of its strategic anatomical position, endothelium is a favorite early target 
organ of cardiovascular risk factors and cardiovascular disease (Thuillez and Richard, 
2005). Intact endothelial function is essential to maintain an adequate vascular tone, to 
prevent platelet aggregation in the intimal surface of blood vessels, to prevent smooth 
muscle proliferation, and to prevent atherosclerosis (He, 2005). Correct vascular tone is 
regulated by a balance between endothelial-derived vasodilators and vasoconstrictors 
that act on the smooth muscle cells of the intima (Blann, 2003). Endothelial dysfunction, 
however, is defined as an impaired endothelium-dependent vasodilatation (for instance 
to ACh) and also is associated with the release of contracting factors, including 
prostanoids and ET-1 (Taddei et al., 2006). A number of cardiovascular disease 
conditions, such as diabetes mellitus and hypertension, share the specific 
pathophysiological feature of endothelial dysfunction.  
 
1.2.1. Diabetes Mellitus Type I 
 Macro- and microvascular complications are the main cause of morbidity and 
mortality in patients with diabetes mellitus (Panus et al., 2003). Endothelial dysfunction 
is considered to be a critical initiating factor leading to the vascular complications of 
diabetes (Triggle et al., 2004). Impaired vasodilator responses to different endothelium-
dependent agonists have been reported and consistently demonstrated in different 
isolated vessels, isolated perfused vascular beds/organs, as well as by in vivo studies that 
involve chemically-induced and genetic models of type I diabetes (Piper and Gross, 
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1988; Endo et al., 1995; Poston and Taylor, 1995). Similarly, impaired endothelium-
dependent vasodilatation has been demonstrated in patients with type I diabetes in the 
absence of clinical complications (Johnstone et al., 1993; Nitenberg et al., 1993; 
Clarkson et al., 1996). Tables 1 (A-C) and 2 summarize some of the studies 
demonstrating endothelial dysfunction in both human and animal models of type I 
diabetes. 
  
There have been many reports concerning the endothelial factors that contribute 
to the attenuation of endothelium-dependent vasodilatation in diabetic models. The 
effects of diabetes on NO-mediated responses have been extensively studied. Several 
studies have clearly demonstrated that endothelial dysfunction can occur despite 
blockade of EDHF and PGI2 synthesis, suggesting a role for deficits of endothelium-
derived NO (Pieper, 1998). Basal NO production has been shown to be diminished in 
diabetes (Pieper, 1997). Additionally, it has been previously reported that agonist-
evoked NO-mediated responses are also reduced in type I diabetes mellitus in both 
animal models and humans (El-Kashef, 1996; Pieper, 1998; De Vriese et al., 2000). To 
our knowledge, there has been no direct measurement of NO from diabetic arteries using 
NO electrode or analysis of NO level in tissues by sensitive assay procedures. According 
to indirect measurements, however, measurement of cGMP levels in rat, and rabbit aorta 
as well as in mesenteric arteries isolated from diabetic animals treated with alloxan 
demonstrated that diabetes decreased both basal and ACh-stimulated cGMP production 
(Abiru et al., 1990; Miller et al., 1994). Treatment with L-NAME was shown to promote 
a greater degree of rightward shift in the dose-response curve to ACh in diabetic rats 
compared to age-matched control rats (Endo et al., 1995). 
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 Despite many investigations reporting impaired NO-mediated responses in 
diabetes, only few studies have focused on the contribution of EDHF to endothelial 
dysfunction in diabetes. It has been reported that diabetes mellitus affects EDHF-
mediated vasodilatation. In the absence of specific inhibitors of EDHF, all evidence to 
date is inevitably indirect. NOS- and COX-resistant vasodialatation to ACh or 
bradykinin was profoundly impaired in the Langendroff perfused hearts, in the isolated 
perfused kidneys, in the isolated renal arteries, as well as in the renal microcirculation in 
vivo (Dae et al., 1993; Fulton et al., 1996; Quilley et al., 1996; De Vriese et al., 1999). 
Other authors, interestingly, observed pronounced deficits of ACh-induced 
hyperpolarization simultaneously with decreased ACh-induced vasodilatation in the 
presence of NOS- and COX-blockade in isolated mesenteric arteries from streptozotocin 
(STZ)-induced diabetic rats and mice (Fukao et al., 1997; Makino et al., 2000; 
Morikawa et al., 2005). In the isolated rat aorta, however, no evidence was found 
concerning a decreased contribution of EDHF to the endothelium-dependent 
vasodilatation (Endo et al., 1995). Since the contribution of EDHF is most prominent in 
smaller vessels, it is not suprising that evidence for a role for EDHF in diabetic 
endothelial dysfunction is restricted to resistance artery and whole organ studies. 
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Table 1. Experimental studies demonstrating endothelium-dependent and -independent 
vasodilatation (EDVD/EIVD) and resroration of the defect.  
A. Isolated  
Vessels 
Reference 
Diabetic 
Model 
Vessel EDVD EIVD Restoration 
Tesfamariam 
et al., 1989; 
1993 
Rabbit, 
AL, 
6w 
Abdominal 
aorta 
   
COX blockade (T) 
TP-RA (T) 
Hattori et al., 
1991 
Rat, STZ, 
8-12w 
Thoracic 
aorta 
  SOD (T) 
catalase 
Cameron & 
Cotter 1992 
Rat, STZ, 
3m 
Thoracic 
aorta 
   
Shimizu et al., 
1993 
Rat, STZ, 
10w 
Thoracic 
aorta 
 
 
 
TP-RA (T) 
 
Otter & Chess-
Williams 1994 
Rat, STZ, 
2w 
 
Thoracic 
aorta 
  
 
Pieper & Peltier 
1995 
Rat, STZ, 
2m 
Thoracic 
aorta  
 
 L-arginine (T) 
Keegan et al 
1995 
Rat. STZ, 
2m 
Thoracic 
aorta 
   
Pieper et al., 
1996 
Rat, BB, 
2m 
Thoracic 
aorta 
  SOD (P) 
Pieper et al., 
1997 
Rat, STZ, 
2m 
Thoracic 
aorta 
   
SOD + catalase (T) 
 
Pieper & 
Siebeneich 
1998 
Rat, STZ, 
2m 
Thoracic 
aorta 
  
 
Taylor et al., 
1992 
Rat, STZ, 
5-6w 
Mesenteric 
artery 
   
Diederich et al., 
1994 
Rat, STZ, 
6-24w 
Mesenteric 
artery 
  SOD (P) 
Heygate et al., 
1995 
Rat, BB, 
6-8w 
Mesenteric 
artery 
  SOD 
catalase (P) 
Fukao et al., 
1997 
Rat, STZ, 
8-12w 
Mesenteric 
artery 
   
Palmer et al., 
1998a, b 
Rat, STZ, 
4-5w 
Mesenteric 
artery 
  
Vitamin (C)(P) 
Vitamin (C+E) (P) 
ACh  SNP  
ACh  SNP  
ACh  
ACh  
Carbachol   SNP  
ACh  
  Nitro 
glycerin  
ACh  
ACh  
ACh  
ACh  SNP  
ACh  SNP  
ACh  SNP  
ACh , BK SNP  
ACh  Pinacidil 
ACh  SNP  
  Nitro 
glycerin  
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Dai et al., 
1993 
Rat, STZ, 
6-24w 
Interlobar 
artery 
  
SOD (N) 
Hill & Ege 
1994 
Rat, STZ, 
4-6w 
Skeletal 
Muscle 
artery 
 
  
 
Morikawa et al., 
2005 
 
Mice, 
STZ, 
10w 
Mesenteric 
artery 
   
COX blockade (P) 
Endo et al., 
1995 
Rat, STZ, 
8w 
Abdominal 
aorta 
  
 
Hopfner et al., 
1999 
Rat,STZ, 
14w 
Thoracic 
aorta 
  
 
Matsumoto et 
al., 2006 
Mice, 
STZ, 
10w 
Mesenteric 
artery 
  
 
Shi et al., 2006 
Rats, 
STZ, 
12w 
Carotid, 
Femoral 
arteries 
  
   L-arginine (T) 
B: Isolated 
Perfused 
Organs 
References 
Diabetes 
Model Organ EDVD EIVD Restoration 
Taylor et al., 
1994b 
Rat, STZ, 
2-10w 
Mesenteric 
bed 
 
  
Quilley et al., 
1996 
Rat, STZ, 
4-6w Heart 
 
 COX blockade (N) 
Fulton et al., 
1996 
Rat, STZ, 
4-6w 
 
Kidney 
  
L-arginine (P) 
Makino et al., 
2000 
   
Rat,STZ, 
      10w 
  
Mesenteric 
      bed 
   
 
      Misurski  
            & 
Gopalakrishnan, 
        2002 
 
 
Rat, STZ, 
    14w 
 
 
Mesenteric  
      bed 
 
 
 
 
 
ACh  SNP  
ACh  
ACh  SNP  
ACh  SNP  
ACh  
BK  
ACh, BK SNP  
ACh  
  Nitro 
glycerin  
ACh  SNP  
ACh  SNP  
ACh  
ACh  
24
 
 
  Kamata et al.,  
         2006 
 
Rat, STZ, 
       w 
 
   Kidney 
   
 
   Rosen et al., 
        1996 
 
Rat, STZ, 
       W 
 
    Heart 
   
SOD (T) 
 
C: In Vivo 
Studies 
References 
 
Diabetic 
Model 
 
Vascular 
Bed 
 
EDVD 
 
EIVD 
 
Restoration 
Bucala et al., 
1991 
 
Rat, STZ, 
0.5-12 m 
 
Blood 
Pressure 
  
Aminoguanidine(P)
Mayhan et al., 
1991 
Rat, STZ, 
2.5-3.5 m 
 
Pial 
arteriols 
  
COX blockade (T) 
Mayhan et al.,  
1997 
Hamster, 
STZ, 2w 
Cheek 
pouch 
arteriols 
  
L-arginine (N) 
Mayhan, 
1997 
Rat, STZ, 
2-2.5 m 
Basilar 
artery 
  
SOD (P) 
Mayhan & Pate, 
1998 
Rat, STZ, 
3-4 w 
Basilar  
artery 
   
Pelligrino et al., 
1994 
Rat, STZ, 
6 m 
Pial 
arteriols 
  
PKC blockade (P) 
Matsunaga et 
al.,  
1996 
Dog, 
AL., 
4w 
Coronary 
circulation 
  
L-arginine (P) 
Koltai et al.,  
1997 
Dog, 
AL., 
3 m 
Coronary 
circulation 
  
L-arginine (N) 
Angulo et al.,  
1998 
Rat, STZ, 
8w 
Hindlimb 
circulation 
  L-arginine (P) 
SOD (P) 
Crijns et al., 
1998 
Rat, STZ, 
6w 
Skeletal 
muscle 
arteriols 
  Aminoguanidine 
(N) 
De Vriese et al., 
1999 
Rat, STZ, 
6w 
Renal 
circulation 
  COX blockade (N) 
 
 
ACh  
ACh  
Substance P 
Histamine  
ACh , BK 
Substance P 
ACh   SNP  
ACh  SNP  
ACh  
ACh  
Sodium  
  nitrite  
ACh  SNP  
ACh  
ACh  Pinacidil  
  Nitro 
glycerin  
  Nitro 
glycerin  
  Nitro 
glycerin  
5-HT  SNP  
ACh  
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Table 2. Clinical studies on endothelium-dependent vasodilatation in diabetes. 
Reference Subjects Vascular bed EDVD EIVD 
Jorgensen et 
al., 
1988 
38 Type I 
21 Control Forearm 
  
Johnstone et 
al., 
1993 
15 Type I 
16 Control Forearm 
  
Nitenberg et 
al., 
1993 
6 Type I 
5 Control 
Coronary 
circulation 
  
Zenere et al., 
1995 
18 Type I 
16 Control Femoral artery 
  
Khan et al., 
1996 
16 Type I 
20 Control Forearm 
  
Clarkson et al., 
1996 
80 Type I 
80 Control Brachial artery 
  
Lekakis et al., 
1997 
31 Type I 
26 Control Brachial artery 
  
Arcaro et al., 
1999 
9 Type I 
17 Control Femoral artery 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FMD 
FMD 
MCh  
SNP 
ACh ISDN 
FMD GTN 
FMD 
MCh  SNP 
FMD GTN 
FMD 
FMD GTN  
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1.3. GHRELIN: A DISCOVERED PEPTIDE DERIVED FROM 
STOMACH 
1.3.1. Endogenous Source, Structure, and Major Forms of the Peptide 
Ghrelin  
 The purified rat ghrelin is a 28-amino acid peptide that is predominately 
produced in the stomach by the enteroendocrine X/A-like cells that represent a major 
endocrine population in the oxyntic mucosal layer of the fundus (Kojima et al., 1999). 
These cells are associated with capillary networks that transport secreted ghrelin into the 
bloodstream for its endocrine actions. Substantially lower amounts of the peptide ghrelin 
have been detected in bowel, pancreas, kidneys, the immune system, placenta, testes, 
pituitary, lung, and hypothalamus (Kojima et al., 1999; Tena-Sempere et al., 2002). 
Ghrelin is the first natural hormone to be identified, in which the hydroxyl group of its 
N-terminal third serine residue (Ser3) is acylated by a hydrophobic moiety, n-octanoic 
acid (Figure 4A, Kojima et al., 1999). An enzyme that catalyzes the acyl-modification of 
ghrelin has not yet been identified. However, a number of acyltransferases have 
previously been identified in mammals; the only reported enzymes that use medium-
chain fatty acids as substrates are carnitine octanoyltransferases, which function in the β-
oxidation of fatty acids (Ramsay and Naismith, 2003). Members of the serine 
acyltransferase family that transfer acyl groups to serine residues of target molecules 
have been identified, including two serine palmitoyltransferases functioning in the 
biosynthesis of sphingolipids in mammals and a plant O-acetyltransferase gene family in 
Arabidopsis thalaiana (Hanada, 2003; Howarth et al., 2003). An acyltransferase has also 
been purified from the gastric mucosa of rat (Kasinathan et al., 1990). This enzyme is an 
27
 
integral rough microsomal protein, catalyzing the transfer of acyl-CoA to mucosal 
proteins. The putative ghrelin Ser O-acyltransferase may have structural homology with 
these acyltransferases (Kojima and Kangawa, 2005).  
  
In mammals, ghrelin homologs have been identified in rat, human, rhesus 
monkey, mouse, mongolian gerbil, cow, pig, sheep, and dog (Kojima and Kangawa, 
2005). The amino acid sequences of mammalian ghrelins are well conserved, in 
particular, the 10 amino acids in their NH2 termini are identical. This structural 
conservation, and the universal requirement for acyl-modification of the third residue, 
indicate that the NH2-terminal region is of central importance to the activity of the 
peptide. The amino acid sequence of human ghrelin differs from rat ghrelin at residues 
11 and 12 with Arg substituted to Lys and Val substituted to Ala (Hosoda et al., 2003).  
 
In the endocrine mucosa of the rat stomach, a second type of ghrelin peptide has 
been also purified and identified as desGln14-ghrelin (Hosoda et al., 2000). DesGln14-
ghrelin has undergone the same process of acylation with n-octanoic acid at its Ser3 
residue as ghrelin and is homologous to ghrelin except that it lacks one glutamine at 
position 14 from the N-terminal. DesGln14-ghrelin is the result of alternative splicing of 
the ghrelin gene, and it seems to possess the same hormonal activities as ghrelin 
(Hosoda et al., 2000). However, desGln14-ghrelin is only present in low amounts in the 
stomach, indicating that ghrelin is the major active form. Both types of the ghrelin 
peptide, either 28- or 27-amino acid residue, are found in tissues and plasma in two 
major forms: n-octanoyl-modified and des-acyl ghrelin (Figure 4B, Hosoda et al., 2000). 
In blood, des-acyl ghrelin circulates in amounts far greater than the acylated ghrelin. 
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Ghrelin in plasma binds to high-density lipoproteins that contain a plasma esterase, 
paraoxonase, and clusterine (Beaumont et al., 2003). Because a fatty acid is attached to 
the Ser3 of ghrelin via an ester bond, paraoxonase, a potent esterase, may be involved in 
deacylation of acyl-modified ghrelin. Thus, des-acyl form of ghrelin may represent 
either a pre-form of acyl-modified ghrelin or the product of its deacylation. 
 
A                                                                B 
 
 
 
 
 
 
Figure 4. Schematic presentation of the molecules A) ghrelin and B) des-acyl ghrelin. 
 
1.3.2. Ghrelin Receptor and its Distribution 
Ghrelin actions are mediated through the ghrelin receptor, also called the growth 
hormone secretagogue receptor (GHS-R), which is a typical G protein-coupled receptor 
(GPCR) with seven transmembrane domains (7-TM) (Howard et al., 1996; Smith et al., 
1999). Two distinct ghrelin receptor cDNAs have been isolated (Howard et al., 1996). 
The first, GHS-R type 1a (GHS-R 1a), encodes a 7-TM GPCR with binding and 
functional properties consistent with its role as ghrelin’s receptor. This type 1a receptor 
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has features characteristic of a typical GPCR, including conserved cysteine residues in 
the first two extracellular loops, several potential sites for posttranslational 
modifications, and an aromatic triplet sequence located immediately after TM-3 in the 
second intracellular loop. Another GHS-R cDNA type 1b, is produced by an alternative 
splicing mechanism (Howard et al., 1996). The GHS-R gene consists of two exons. The 
first exon encodes TM-1 to TM-5, and the second exon encodes TM-6 to TM-7. Type 1b 
is derived from only the first exon and encodes only five of the seven predicted TM 
domains. The type 1b receptor is thus a COOH-terminal truncated form of the type 1a 
receptor and is pharmacologically inactive. 
 
The active ghrelin receptor (GHS-R 1a) is well conserved across a number of 
mammals. This strict conservation suggests that ghrelin and its receptor serve important 
physiological functions (Kojima and Kangawa, 2005). However, it is suggested that a 
novel unidentified subtype of ghrelin receptor also exists. Des-acyl ghrelin does not 
displace radiolabeled ghrelin at the binding sites of acylated ghrelin in hypothalamus 
and pituitary, and therefore shows no endocrine activities in either humans or rats. On 
the other hand, both ghrelin and des-acyl ghrelin bind to H9C2 cardiomyocytes, which 
do not express the ghrelin receptor (Baldanzi et al., 2002). 
 
GHS-R 1a messenger ribonucleic acid (mRNA) is mainly expressed in multiple 
hypothalamic nuclei, including arcuate (ARC), ventromedial (VMN), dorsomotor, and 
solitary tract, and in the anterior pituitary somatotrophs. However, lower levels of the 
receptor has been detected in other areas of the brain such as the dentate gyrus, CA2, 
and CA3 regions of the hippocampus, the substantia nigra, the ventral tegmental area, 
30
 
and the dorsal and median raphe nuclei (Howard et al., 1996; Guan et al., 1997). Reverse 
transcriptase polymerase chain reaction (RT-PCR) analyses also demonstrated ghrelin 
receptor mRNA expression in many peripheral organs, including cardiovascular, lung, 
liver, kidney, pancreas, stomach, small and large intestines, adipose tissue, and immune 
cells, indicating that ghrelin has multiple functions in these tissues (Broglio et al., 2001; 
Kojima et al., 2001). 
 
1.3.3. Physiological Functions of Ghrelin 
 Physiological fuctions of ghrelin could be classified into three different 
categories: 
(1) Hypothalamic-Pituitary actions of ghrelin: growth hormone (GH)-releasing activity, 
prolactin (PRL)- and adrenocorticotropin hormone (ACTH)-releasing activities. 
(2) Central actions of ghrelin: food intake and appetite regulation, effects on sleep, 
effects on behavior.  
(3) Peripheral activities of ghrelin: cardiovascular and hemodynamic effects, 
gastroenteropancreatic actions, modulation of proliferation of neoplastic cells.    
 
1.3.3.1. GH-Releasing Activity 
GH secretion is regulated by the interaction between the hypothalamic peptide 
growth hormone releasing hormone (GHRH), which stimulates, and somatostatin, which 
inhibits, GH secretion from the pituitary. These two factors also influence GH pulses, as 
human GH is released in 10-20 pulses in each 24 hr cycle (Roelfsema et al., 2001). The 
timing of these pulses is controlled by intermittent somatostatin secretion whereas the 
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amplitude by GHRH (Roelfsema et al., 2001). Recently, ghrelin was identified as the 
third endogenous factor responsible for regulation of GH release. Ghrelin stimulates GH 
release both in vitro and in vivo in a dose-dependent manner. It has been shown that 
ghrelin stimulates GH release from pituitary cells in vitro (Kojima et al., 1999). 
Similarly, intracerebroventricular, as well as intravenous, ghrelin administration in rats 
resulted in increase in GH secretion (Date et al., 2000; Seoane et al., 2000). In humans, 
ghrelin also specifically induced GH secretion and the observed effect was stronger as 
compared to that of GHRH (Arvat et al., 2000; Takaya et al., 2000). 
 
The cellular mechanisms and the signal transduction pathway involved in the 
GH-releasing activity of ghrelin appear to be distinct from the one of GHRH. Ghrelin 
stimulates GH secretion via activation of GHS-R 1a receptors (Lazarczyk et al., 2003). 
In contrast to GHRH, which activates AC resulting in increased intracellular cAMP 
levels in pituitary cells upon activation of GHRH receptors, ghrelin causes a transient 
increase in [Ca2+]i in somatotrophs (Chen et al., 1996). Binding of ghrelin to its receptor 
activates the phospholipase C signaling pathway, leading to increased inositol phosphate 
turnover and protein kinase C activation, followed by the release of Ca2+ from 
intracellular stores. GHS-R 1a activation also leads to an inhibition of K+ channels, 
allowing the entry of Ca2+ through voltage-gated L-type channels (Chen et al., 1996).  
 
The n-octanoyl group at the Ser3 residue of the ghrelin molecule seems to be 
essential for the binding to the receptor and the bioactivity of the hormone, at least in 
terms of GH release. In fact, the non-acylated ghrelin is known to be devoid of any GH-
releasing activity in both rats and humans (Bowers 2001; Broglio et al., 2003). 
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1.3.3.2. Food Intake and Appetite Regulation 
 Feeding is a basic behavior that is necessary for life. Long-term lack of food 
results in death. It is well accepted that appetite is controlled by the brain and that 
feeding behavior is regulated by complex mechanisms in the central nervous system, in 
particular the hypothalamus (Schwartz et al., 2000). Removal of the lateral 
hypothalamus causes hypophagia, leading to death due to severe weight loss. On the 
other hand, removal of the ventromedial hypothalamus causes hyperphagia and obesity.  
  
Recent identification of appetite-regulating humoral factors reveals regulatory 
mechanisms not only in the central nervous system, but also mediated by factors 
secreted from peripheral tissues (Neary et al., 2004; Ukkola, 2004). Leptin, produced in 
adipose tissues, is an appetite-suppressing factor that transmits satiety signals to the 
brain (Friedman, 2002). Hunger signals from peripheral tissues, however, had remained 
unidentified until the discovery of ghrelin. Plasma ghrelin levels increase immediately 
before each meal and fall to minimum levels within 1h after eating (Tschop et al., 2001). 
The clear preprandial rise and postprandial fall in plasma ghrelin levels support the 
hypothesis that ghrelin is an initiation signal for meal consumption. Indeed, ghrelin 
levels and hunger scores have shown to be positively correlated. Furthermore, the 
postprandial suppression of plasma ghrelin level is proportional to the ingested caloric 
load, further reinforcing the hypothesis that ghrelin is a hunger signal (Callahan et al., 
2004). Additionally, ghrelin gene expression in the stomach as well as plasma ghrelin 
concentrations are increased in fasting conditions and reduced after habitual feeding 
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(Tschop et al., 2001). Ghrelin has been found to be the most powerful orexigenic 
peptide.                                                                                                                                                          
 
Chronic intracerebroventricular injection of ghrelin in rats increases their 
cumulative food intake and decreases energy expenditure, resulting in body weight gain. 
Ghrelin-treated mice also increase their fat mass, both absolutely and as a percentage of 
total body weight (Tschop et al., 2000; Nakazato et al., 2001; Wren et al., 2001). Not 
only intracerebroventricular injection, but also intravenous and subcutaneous injections 
of ghrelin have been shown to increase food intake and body weight gain (Tschop et al., 
2000). Plasma ghrelin levels were lower in obese subjects than the age-matched lean 
controls (Tschop et al., 2001; Shiiya et al., 2002). Moreover, plasma ghrelin 
concentrations were significantly lower in Pima Indians, who are prone to develop 
insulin resistance and obesity, than in Caucasians (Tschop et al., 2001).  
  
The mechanism of appetite stimulation by ghrelin is not yet fully identified. 
Immunohistochemical analyses indicate that ghrelin-containing neurons are present in 
the ARC nucleus of the hypothalamus, a region involved in appetite regulation (Kojima 
et al., 1999). In the ARC, these ghrelin-containing neurons send efferent fibers onto 
neuropeptide Y (NPY)- and agouti gene-related peptide (AGRP)-expressing neurons to 
stimulate the release of these orexigenic peptides, and onto proopiomelanocortin 
(POMC) neurons to suppress the release of this anorexigenic peptide. Therefore, at least 
part of the orexigenic effect of ghrelin is suggested to be mediated by inducing the genes 
encoding the potent appetite stimulants NPY and AGRP (Kojima and Kangawa, 2005). 
The appetite-stimulating effects of ghrelin are blocked by an antagonist of NPY 
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receptor. In addition, intracerebroventricular injection of an AGRP inhibitor, anti-NPY 
immunoglobulin G (IgG), or anti-AGRP IgG, inhibits the appetite-stimulating effect of 
ghrelin (Cowley et al., 2003). Studies with knockout mice confirmed these results. 
Although deletion of either NPY or AGRP caused a modest or no effect on the 
orexigenic action of ghrelin, the double knockout mice lacked the action of ghrelin 
completely (Chen et al., 2004).  
  
Peripherally injected ghrelin also is shown to stimulate hypothalamic neurons 
and stimulate food intake (Wren et al., 2001; Date et al., 2002). However, the rate at 
which peripheral ghrelin passes the blood-brain barrier has been shown to be very low. 
Thus, peripheral ghrelin must activate the appropriate hypothalamic regions via an 
indirect pathway (Kojima and Kangawa, 2005). The detection of ghrelin receptors on 
vagal afferent neurons in the rat nodose ganglion suggests that ghrelin signals from the 
stomach are transmitted to the brain via the vagus nerve (Date et al., 2002). Vagotomy 
has been shown to inhibit the ability of ghrelin to stimulate food intake (Andrews and 
Sanger, 2002; Date et al., 2002). 
 
1.3.3.3. Cardiovascular and Hemodynamic Effects 
 Expression of mRNA encoding both ghrelin and its receptor GHS-R 1a has been 
demonstrated in heart and aorta (Nagaya et al., 2001). Specific binding sites for 
radiolabeled ghrelin, [125I-His9] ghrelin, have been identified in rat heart and human 
peripheral arteries, where the density of ghrelin receptors is up-regulated with 
atherosclerosis (Katugampola et al., 2001). This evidence may suggest the involvement 
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of ghrelin in cardiovascular function. In agreement with the presence of ghrelin 
receptors in the cardiovascular system, there is already evidence that ghrelin mediates 
GH-independent cardiovascular activities, both in animals and humans. Chronic 
administration of ghrelin is able to improve cardiac contractility in GH-deficient rats 
(Nagaya et al., 2001). In humans, intra-arterial infusion of ghrelin increased forearm 
blood flow in a dose-dependent manner, in spite of unchanged serum level of insulin-
like growth factor-1 (IGF-1) (Okumura et al., 2002). An intravenous bolus injection of 
ghrelin into human volunteers decreased mean arterial pressure (MAP) without changing 
the heart rate (Nagaya et al., 2001 a, and b). Ghrelin also increased the cardiac index and 
stroke volume indices.  Rats with chronic heart failure that were treated with ghrelin 
showed higher cardiac output, stroke volume, and left ventricular function compared 
with afflicted, but placebo-treated controls (Nagaya and Kangawa, 2003). Furthermore, 
ghrelin increased the diastolic thickness of the noninfarcted posterior wall, inhibited left 
ventricle enlargement, and increased left ventricular fractional shortening in these 
chronic heart failure rats (Nagaya et al., 2001). Thus, ghrelin improves left ventricular 
dysfunction and attenuates the development of left ventricular remodeling and cardiac 
cachexia (Nagaya and Kangawa, 2003 b). Moreover, prolonged administration of ghrelin 
in chronic heart failure rats is associated with a reduction of systemic vascular 
resistance. The decrease in systemic vascular resistance in response to ghrelin was 
accompanied by a concomitant reduction in MAP in patients with chronic heart failure 
(Enomoto et al., 2003).  
 
The decrease in MAP induced by ghrelin seems to occur, at least in part, through 
its indirect action on the nucleus of the solitary tract (Matsumura et al., 2002; Lin et al., 
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2004). Microinjection of ghrelin into this nucleus significantly decreased MAP and heart 
rate. This injection also suppressed sympathetic activity. The effect of ghrelin on the 
local vasodilator factors produced in the cardiovascular system, however, can not be 
neglected. Ghrelin-evoked decrease in MAP was much greater in rats subjected to NOS 
inhibition (Shinde et al., 2005). In addition, intravenous infusion of apamin and ChTX , 
a combination that is known to block KCa channels or the EDHF process, attenuated the 
decrease in MAP evoked by ghrelin in both control and NOS-inhibited rats (Shinde et 
al., 2005).  
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2. PRESENT INVESTIGATION 
2.1. Working Hypothesis 
(1) Both ghrelin and des-acyl ghrelin possess potent endothelium-dependent vasodilator 
responses in mesenteric vascular bed (MVB). Vasodilator effects in MVB in response to 
the natural ligand of the GHSR-1a receptors, ghrelin, are possibly mediated through the 
generation of EDHF. The released EDHF stimulates KCa channels and increases K+ 
conductance, resulting in smooth muscle relaxation. Therefore, inclusion of the NO 
synthase inhibitor (NOSI) N (G)-nitro-L-arginine methyl ester (L-NAME), COX 
inhibitor indomethacin, or the KATP channel blocker glibenclamide, fails to abolish the 
vasodilator responses to ghrelin. However, pretreatment of MVB with either a high 
extracellular K+ concentration (80 mmol/L KCl), or different selective and nonselective 
KCa channel blockers [TBA (tetrabutylammonium), apamin + ChTX, apamin + TRAM-
34 (1-(2-chlorophenyl) diphenylmethyl)-1H-pyrazole]] abolishes the vasodilator 
responses to ghrelin. 
 
(2) The vasodilator action of ghrelin is not mediated by the classical GHSR-1a receptors 
present in the pituitary. But, it is mediated by the activation of a novel receptor present 
on the endothelium. Treatment of MVB with antagonists of the GHSR-1a receptors, 
such as [D-Lys3]-growth hormone releasing peptide-6 ([D-Lys3]-GHRP-6) or the peptide 
L-756867, does not block the vasodilator actions of ghrelin.  
 
(3) The whole ghrelin molecule, which is a 28-amino acid peptide with an n-octanoyl 
group on the Ser3, is not necessary for its vasodilator activity. Des-acyl ghrelin, which is 
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a form of ghrelin without n-octanoic acid on the Ser3 residue, can also cause 
vasodilatation to the same extent as ghrelin in MVB.  
 
(4) Taking into account the direct cardiovascular effects of ghrelin, it would be 
interesting if ghrelin could be administered orally in patients with cardiovascular 
diseases and chronic heart failure. However, since ghrelin is a peptide hormone, it is 
mostly degraded in the stomach by peptidases. Thus, due to the lower bioavailability of 
the peptidyl growth hormone secretagogues (GHSs), the development of selective non-
peptide agonists directed to the novel vascular receptors of ghrelin would be a new drug 
investigation for the management of cardiovascular diseases. Besides ghelin, orally 
active non-peptide agonists of the classical GHSR-1a receptors, L-166446 and L-
163255, are also effective vasodilators in MVB. These non-peptides, therefore, could be 
used as orally administered agents in the management of cardiovascular disease.  
 
(5) In STZ-induced diabetic rats, plasma ghrelin levels are elevated due to low plasma 
insulin levels. The decreased MVB resistance and exaggerated vasodilator response to 
agonists in early stages of STZ diabetic rats are due to increased ghrelin levels, which 
promote enhanced vasodilatation via activation of novel vascular ghrelin receptors. At 
later stages of STZ diabetes, the enhanced effect due to ghrelin is countered by down-
regulation of vascular ghrelin receptors. In addition, in later stages of STZ diabetes, 
EDHF response is impaired, which itself would affect the vascular responses to ghrelin 
as ghrelin response is dependent on EDHF. The same condition seems to happen in 
fasted rats. Plasma ghrelin levels are elevated during fasting because of decreased 
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plasma glucose and insulin concentrations. Ghrelin, then, acts on its vascular receptors 
and induces vasodilatation.  
 
2.2 Rationale for the Study 
Six major pieces of evidence provide the basis and foundation for undertaking 
investigations on ghrelin-evoked vasodilator responses in MVB of Sprague Dawley 
(SD) rats. They are as follows: 
 
(1) Intravenous bolus injection of ghrelin (10 μg/Kg) led to a significant decrease in 
MAP with increased cardiac output within 15 min that lasted for about one hr in both 
normal volunteers and chronic heart failure patients (Nagaya et al., 2001 a). Systemic 
administration of ghrelin in conscious rats led to a dose-dependent decrease in blood 
pressure (20 mmHg by 10 min-10 nmol/L/rat) that lasted for 30 min (Nagaya et al., 
2001b). Ghrelin was shown to be an effective endothelium-independent vasodilator of 
the long-lasting constrictor ET-1 in human mammary arteries (Wiley and Davenport, 
2002). In contrast, 3-week treatment with ghrelin improved endothelial dysfunction 
demonstrated by impaired ACh-induced vasodilatation in GH-deficient rats (Shimizu et 
al., 2003). On the other hand, intra-arterial infusion of ghrelin reduced the forearm 
vascular resistance that was not accompanied by changes in plasma cyclic nucleotide 
(cAMP and cGMP) levels. Since a NOSI failed to block the responses, it was concluded 
that the vasodilator effect of ghrelin was not mediated by NO generation (Okumura et 
al., 2002). Previous data from our laboratory also demonstrated that ghrelin-evoked 
decrease in MAP was much greater in rats subjected to NOS inhibition. In addition, 
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intravenous infusion of apamin + ChTX attenuated the decrease in MAP evoked by 
ghrelin in both control and NOS-inhibited rats (Shinde et al., 2005). 
 
(2) In addition to ghrelin, a natural ligand of the classical GHSR-1a receptors, synthetic 
GHSs, also feature a variety of cardiovascular activities (Locatelliot et al., 1999; Nagaya 
et al., 2001 a and b; Baldanzi et al., 2002; Okumura et al., 2002; Benso et al., 2004). 
Hexarelin, a peptidyl GHS, has been shown to improve cardiac function and decrease 
peripheral vascular resistance in rats with myocardial infarction and to protect the 
isolated heart from ventricular dysfunction (Rossoni et al., 2000; Tivesten et al., 2001). 
Hexarelin was also demonstrated to induce a dose-dependent increase in coronary 
perfusion pressure in isolated perfused hearts (Bodart et al., 2003). In contrast, Bedendi 
et al. (2003) showed a negative ionotropic effect induced by hexarelin in the rat and 
guinea pig papillary muscles. A stimulatory effect on cell proliferation and an 
antiapoptotic action of GHSs on the cardiomyocyte cell line H9C2 and EC have also 
been shown (Filigheddu et al., 2001; Baldanzi et al., 2002; Petterson et al., 2002). Both 
MK-0677 and hexarelin, a non-peptidyl and peptidyl synthetic GHS, respectively, 
inhibited the cell death in cardiomyocyte and EC lines (Baldanzi et al., 2002). In hearts 
subjected to 30 min of ischemia followed by 120 min of reperfusion, however, the 
synthetic peptidyl secretagogue hexarelin significantly reduced infarct size, while the 
non-peptidyl secretagogue MK-0677 was ineffective (Frascarelli et al., 2003).  
 
(3) Ghrelin strongly stimulates GH secretion acting on a specific GPCR, namely GHSR-
1a receptor, which is different from the GHRH-receptor (Muccioli et al., 2002). 
Expression of GHSR-1a receptors has been demonstrated at the myocardial level and 
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within the vasculature (Nagaya and Kangawa, 2003). Bedendi et al. (2003) found 
unexpectedly that the non-acylated form of ghrelin was able to exert a negative 
ionotropic effect on the rat as well as guinea pig papillary muscles to even a greater 
extent than the acylated ghrelin, even though unacylated ghrelin is generally assumed to 
be devoid of biological activity, as it can not bind to or activate the GHSR-1a receptors 
(Bednarek et al., 2001). The binding studies performed by Bednarek et al. (2003) with 
either acylated and unacylated ghrelin confirmed that there is a specific receptor 
recognized by all ghrelin forms and by hexarelin as well. These findings therefore 
indicate the existence of a cardiac non-GHS type 1a receptor involved in the 
cardiovascular actions of ghrelin and des-acyl ghrelin. It has been reported previously 
that both ghrelin and des-acyl ghrelin bind to a common receptor in breast cancer cells 
(Cassoni et al., 2001). In these cells, ghrelin and des-acyl ghrelin inhibit cell 
proliferation, whereas, on the other hand, GHSR-1a receptors appeared to mediate a 
proliferative signal (Murata et al., 2002). Additionally, the recent finding that H9C2 
cardiomyocytes do not express GHSR-1a receptors, but have high affinity binding sites, 
common for ghrelin and des-acyl ghrelin, involved in mediating their antiapoptotic 
activity, provides further support to the hypothesis that multiple ghrelin and GHS 
receptors exist in the cardiovascular system (Baldanzi et al., 2002). Each receptor may 
then contribute independently to the wide array of cardiovascular activities induced by 
ghrelin, synthetic GHSs, and endogenous ghrelin-derived molecules (Torsello et al., 
2003). Furthermore, the recent data from our laboratory demonstrating the 
characterization of [125I] ghrelin binding sites in mesenteric artery EC, provided another 
piece of evidence suggesting that the vasodilatory effect of ghrelin may not be mediated 
by GHSR-1a receptors. Des-acyl ghrelin was shown to bind to pituitary GHSR-1a 
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receptors with much lower affinity (3500 nmol/L) compared to the high affinity (1.5 
nmol/L) interaction by ghrelin (Matsumoto et al., 2001). On the contrary, our laboratory 
reported that des-acyl ghrelin displaced [125I] ghrelin specific binding to EC with a 
higher affinity (215 pmol/L) than ghrelin (330 pmol/L).  
 
 The existence of different GHS receptor subtypes in the heart has already been 
demonstrated (Muccioli et al., 2000 and 2002). GHSR-1b receptors, a GHSR-1-
truncated splicing variant, although expressed in the heart, did not appear to be 
functional (Howard et al., 1996). CD36, a fatty acid receptor, has been identified 
recently as a myocardial receptor for hexarelin. However, neither ghrelin nor the 
synthetic non-peptidyl GHS, MK-0677, recognize such a receptor (Bodart et al., 2002). 
In contrast, Bedendi et al. (2003) demonstrated that there is a non-GHSR-1a receptor 
that is recognized by all ghrelin forms and by hexarelin as well.  
 
(4) Several studies elucidated the structural features of the peptide ghrelin necessary for 
its efficient binding to and activation of the classical GHSR-1a receptors (Bednarek et 
al., 2000; Matsumoto et al., 2001). The n-octanoic acid modification of ghrelin on the 
third amino acid residue appeared to be necessary for its GH-releasing activity (Kojima 
et al., 1999 and 2000). The study by Bednarek et al. (2000) demonstrated that the entire 
sequence of ghrelin is not necessary for activation of GHSR-1a receptors. The short 
peptides encompassing the first four or five residues of ghrelin were found to activate 
the GHSR-1a receptors about as efficiently as the full-length ghrelin, thus implying that 
the N-terminal Gly-Ser-Ser(n-octanoyl)-Phe segment constitutes the “essential core” 
required for efficient binding to and activation of GHSR-1a receptors.  
43
 
(5) Early type I diabetes is associated with changes in vascular function leading to over-
perfusion of the vasculature, whereas the later stages are associated with atherosclerotic 
and hypertensive changes, promoting the well-known late stage complications of the 
disease (Epstein and Sowers, 1995; Pieper, 1998). While the mechanisms of these 
changes are not completely understood, it is possible that shifts in the actions of 
endothelial derived relaxing and contracting factors might contribute. Impaired 
endothelial-dependent vasodilatation is considered as a major risk factor of 
cardiovascular complications of type I diabetes (Triggle et al., 2004). Impaired 
endothelium-dependent vasodilatation can be directly linked to a reduction in the 
bioavailability/bioactivity of endothelium-derived NO (Pieper, 1998; De Vriese et al., 
2000). There is now accumulating a body of evidence in type I diabetic mice, rats and 
humans showing impaired EDHF activity, especially in small resistance vessels (Fukao 
et al., 1997; Makino et al., 2000; Fitzgerald et al., 2005; Morikawa et al., 2005). Fukao 
et al. (1997) showed that the amplitude and duration of the hyperpolarization produced 
by ACh was significantly decreased in mesenteric arteries from diabetic rats. Inhibition 
of NOS did not affect the hyperpolarization response to ACh in mesenteric arteries from 
control and diabetic rats, thus concluding that the functional EDHF response is 
decreased in the rat mesenteric artery as a result of diabetes. 
 
(6) It has been demonstrated that plasma ghrelin levels are elevated in STZ-treated 
diabetic rats (Ishii et al., 2002; Gellings et al., 2004). While plasma ghrelin levels and 
the gastric preproghrelin mRNA expression levels in the stomach are significantly 
higher in STZ diabetic rats, their gastric levels and the number of ghrelin-
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immunoreactive cells in the gastric fundus are relatively lower in STZ-induced diabetic 
rats (Masaoka et al., 2003).  
 
2.3. Objectives 
 Based on the following objectives, I will attempt to validate my working 
hypothesis: 
(1) To evaluate the vasodilator responses evoked by ghrelin and des-acyl ghrelin in 
MVB, with an emphasis on the underlying mechanisms by which ghrelin produces 
vasodilatation in the perfused rat MVB. 
 
(2) To evaluate if the vasodilator responses evoked by ghrelin in the MVB are mediated 
through the activation of GHSR-1a receptors present on vascular tissues. 
 
(3) To evaluate the vasodilator activities of the synthetic non-peptide agonists of GHSR-
1a receptors, L-166446 and L-163255 (Spiroindanyl piperidines). 
 
(4) To evaluate the structure-activity relationship of the ghrelin-related peptides in 
relation to their vasodilatory effects. 
 
(5) To evaluate the vasodilator responses to ghrelin, in both conditions of fasting and 
STZ-induced diabetes, in relation to the plasma ghrelin concentrations.  
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3. MATERIALS AND METHODS 
3.1. Animals 
The care and use of animals used in the present study conformed to the 
regulations stipulated by the University of Saskatchewan Animal Care Committee. We 
followed similar guidelines as established by the US National Institutes of Health for the 
maintenance and use of experimental animals in our laboratories (NIH Publication No. 
85: 23, 1996). Male SD rats were purchased from Charles River (St. Constant, Quebec, 
Canada) at an age of 11 weeks. They were housed in our animal quarters assigned to the 
Department of Pharmacology with due care under standardized conditions with a 
light/dark cycle of 12 hr and a constant temperature of 22 ± 1ºC. The rats were fed ad 
libitum with food pellets (Purina Rat Chow) and tap water. The animals were utilized for 
experiments when they reached the age of 12 weeks. 
 
3.2. Chemicals and Reagents 
3.2.1. Chemicals for Evaluation of Vasodilator Responses to Agonists 
 ACh, phenylephrine hydrochloride (PE: a-(1-Aminoethyl)-2,5- 
imethoxybenzylalcohol), indomethacin, L-NAME, barium chloride dehydrate (Ba2+), 
glibenclamide, ouabain, TBA, and sodium nitroprusside (SNP), were all purchased from 
Sigma-Aldrich Chemical Co., Oakville, ON., Canada. Apamin and ChTX were obtained 
from EMD Biosciences Inc. (La Jolla, CA, USA). TRAM-34 was purchased from Sigma 
(St. Louis, MO). [D-Lys3]-GHRP-6 and synthetic rat Ser3-(n-octanoyl)-ghrelin were 
from either Bachem (Torrance, CA, USA) or from Phoenix Pharmaceuticals Inc. 
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(Belmont, CA, USA), while the des-acyl form of ghrelin, rat Ser3(des-octanoyl)-ghrelin, 
was obtained from Phoenix Pharmaceuticals Inc. (Belmont, CA, USA). 
  
3.2.2. Chemicals for STZ-Induced Diabetes 
  STZ was obtained from Sigma-Aldrich (Milwaukee, Wis., USA). 
Radioimmunoassay (RIA) kits for the detection of ghrelin and insulin in samples were 
purchased from Phoenix Pharmaceuticals (Belmont, CA) and Amersham (Oakville, 
ON), respectively. One Touch Basic Glucometer and the One Touch Basic Glucose 
Strips were from Lifescan (Vancouver, BC).     
 
3.3. Methods 
3.3.1. Rat MVB Preparation 
3.3.1.1. Isolation of MVB 
 Experiments were performed when animals reached the age of 12 weeks. Rats 
were anesthetized with thiopental sodium (100 mg/Kg, i.p.), laprotomy was performed 
by a mid-line incision and the heart was removed. Immediately after the removal of the 
heart, the superior mesenteric artery was identified and cleared of any adherent tissue 
using a cotton swab. Using forceps, two pieces of sutures were placed under the superior 
mesenteric artery at the level of the T-junction where the superior mesenteric artery 
branches off from the abdominal aorta. A small incision was made at the T-junction and 
the superior mesenteric artery was cannulated with polyethylene tubing fitted on to the 
20 gauge, dissected from the gastrointestinal tract, and placed in a warm (37 ± 1ºC) 
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Krebs solution. The MVB was then transferred and connected to the perfusion apparatus 
(Misurski, Tatchum-Talom et al., 2000; Shastri, McNeill et al., 2001). 
 
3.3.1.2. Perfusion of MVB 
 The MVB was perfused via the cannula with a modified Krebs bicarbonate 
solution (pH 7.4) by means of Gilson constant flow pump, at a constant flow rate of 5 
ml/min. The composition of the Krebs buffer solution (in mM) was: NaCl 118, KCl 4.7, 
MgCl2 6H2O 1.2, CaCl2.2H2O 1.8, KH2PO4 1.2, NaHCO3 25, Glucose 11.1. The buffer 
was continuously oxygenated using carbogen (O2 95% oxygen + with 5% CO2) and 
maintained at a steady temperature 37 ± 1ºC with the thermocirculator (from Harvard 
Apparatus). An air pocket was incorporated in the circuit for air entrapment in the 
perfusate system to prevent denudation of the endothelium (Misurski, Tatchum-Talom et 
al., 2000; Shastri, McNeill et al., 2001).  
 
3.3.1.3. Measurement of Perfusion Pressure Changes to Agonists and 
Antagonists  
 The changes in perfusion pressure (PP) monitored as mmHg in response to 
agonists and antagonists, were measured using a strain gauge pressure transducer placed 
in the circuit, before monitoring the MVB preparation. A chart program (Chart V4.0.1) 
using a PowerLab/8SP Series system (AD Instruments Pty. Ltd., Castlehill, NSW, 
Australia) electronically integrated and recorded the pressure signals. The pressure 
change was subjected to an initial external calibration using a sphygmomanometer. 
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3.3.2. Experimental Protocol 
3.3.2.1. Equilibration of MVB Preparation 
 The preparations were allowed to equilibrate for 1 hr with normal Krebs buffer to 
attain steady state baseline PP. Then, two bolus doses of PE (80 μmol/L), a non-selective 
α1 agonist, were given in succession to ensure reproducible constrictor responses could 
be attained. In all preparations, before performing the concentration-response (CR) 
curves or single-dose responses to different vasodilator agonists, PE (80 μmol/L) was 
perfused for a period of about 20 min to evoke a consistent and stable vasoconstrictor 
response. 
 
3.3.2.2. Concentration-Response Curves to Vasodilator Agonists 
 Graded dilator responses to serially increasing concentrations of either ACh (10 
pmol/L-10 μmol/L), ghrelin (100 fmol/L-100 nmol/L), or des-acyl ghrelin (100 fmol/L-
100 nmol/L) were determined by perfusing appropriate concentrations of the respective 
agonist in a maximum volume of 20-25 ml. The experiments were performed each day 
by perfusing two MVBs isolated from two SD rats in parallel under identical conditions 
using the three mentioned agonists. The order in which the agonists were given did not 
affect the pattern of their responses. A minimum of 45 min was provided for the tissues 
to recover after completing the CR protocol to one agonist before a similar protocol was 
initiated with a serially increasing concentration of the second agonist. In several 
experiments, to confirm that no desensitization had occured to these vasodilators, we 
conducted the CR curves to each of these dilators more than once in the same MVB 
preparation. The results demonstrated that the same CR curves could be repeated as long 
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as the concentrations of ghrelin or des-acyl ghrelin did not exceed 1 nmol/L. After 
completing the control responses, the CR protocols to the two vasodilators ghrelin and 
ACh were repeated in the presence of different inhibitors of NO- and EDHF-mediated 
pathways of vasodilatation including L-NAME (100 μmol/L), TBA (0.5 mmol/L), L-
NAME + TBA, and KCl (80 mmol/L). These different inhibitors of the NO- and EDHF-
mediated pathways of vasodilatation were present in the perfusion buffer for a period of 
30 min and also during the serial addition of increasing concentrations of either ghrelin 
or ACh in PE-containing buffer.  
 
In addition to evaluating the responses to ghrelin, des-acyl ghrelin, and ACh, CR 
curves to the increasing concentrations (100 fmol/L-100 nmol/L) of the two synthetic 
non-peptide agonists of the classical GHSR-1a receptors, L-166446 and L-163255, were 
also determined in PE-contracted MVB preparations. Both non-peptide agonists, were 
H2O-soluble. However, we tend to solubilize all small molecule compounds in a very 
small quantity of dimethyl sulfoxide (DMSO).       
 
3.3.2.3. Responses to a Single Dose of Vasodilator Agonists   
 The vasodilator response to a single dose of either ghrelin (1 nmol/L) or ACh (1 
μmol/L), which produces maximal relaxation in PE-contracted MVB preparations, were 
assessed in the presence and in the absence of different inhibitors of COX, NO, and 
EDHF pathways of vasodilatation including: indomethacin (10 μmol/L), apamin (1 
μmol/L) + ChTX (100 nmol/L), apamin + TRAM-34 (10 μmol/L), ouabain (10 μmol/L) 
+ Ba2+ (30 mmol/L), and glibenclamide (10 μmol/L). The stock concentration of 
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indomethacin was dissolved in sodium carbonate (0.01 mol/L). TRAM-34 stock 
concentration was dissolved in DMSO. To make up the final concentrations, further 
dilutions were made using Krebs buffer. Vasodilator responses to a single concentration 
of ghrelin were also evaluated in the presence of different blockers of the classical 
GHSR-1a receptors, [D-Lys3]-GHRP-6 (10 nmol/L) as well as L-756867 (a synthetic 
peptide antagonist, 1 μmol/L). L-756867 was best solubilized in dilute acidified H2O 
(0.01N acetic acid).  
 
 In addition to evaluating the vasodilator responses in the normal SD rats, 
vasodilator responses to single concentrations of ghrelin and ACh were also determined 
in either fully fed or fasted rats that were subjected to STZ-induced diabetes for 4 or 8 
weeks. In each day, the experiments were performed by perfusing two MVBs isolated 
from either 4- or 8-weeks fed/fasted diabetic versus control rats in parallel under the 
same conditions using both agonists.  
 
3.3.2.4. Removal of Endothelium 
 CR curves to ghrelin (10 pmol/L-1 nmol/L), des-acyl ghrelin (10 pmol/L-1 
nmol/L), and ACh (10 nmol/L-1 μmol/L) were also done in the absence of endothelium. 
Removal of endothelium was achieved by slow and intermittent infusion of 10 ml air at 
5 min intervals through a port for 1hr. In the MVB, endothelium removal led to a rise in 
the tone of the MVB. The injection of air into the MVB led to the removal of 85-90% of 
the EC from the vascular bed. In each experiment, the removal of endothelium was 
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confirmed by demonstrating a lack of responsiveness to a test dose of ACh (100 μmol/L) 
in the MVB constricted with 80 μmol/L of PE subsequent to the exposure to air.  
 
3.3.3. STZ Treatment 
 At 12 weeks of age, SD rats were fasted overnight and divided into two groups 
of diabetic and control rats. Diabetic animals were given a single intraperitoneal (i.p.) 
injection of STZ in citrate buffer (65 mg/Kg, pH 4.5). Control rats, in contrast, were 
treated with a single i.p. injection of citrate buffer alone. Blood glucose levels were 
assessed one week post-treatment to verify hyperglycemia (>15 mmol/L). Following the 
treatment with STZ or citrate buffer, STZ-treated as well as control rats were kept for 
the period of either 4 or 8 weeks. After 4 or 8 weeks of treatment, the rats in each group 
were again divided into two groups of either fasted (4- or 8-weeks diabetic fasted, 
control fasted) or fed (4- or 8-weeks diabetic fed, control fed) for overnight. The 
experiments were then performed on the following day, after the rats were anesthetized 
using thiopental sodium (100 mg/Kg, i.p.). 
 
3.3.4. Blood Glucose Monitoring 
 Using a scalpel blade, a small incision was made on the tail vein. A drop of 
blood was then applied to a glucose strip (One Touch Basic Glucose Strips, Lifescan, 
Vancouver, B.C.) placed on the glucometer (One Touch Basic Glucometer). Glucose in 
the drop of blood was measured by the glucose oxidase method. Pressure was 
subsequently applied to the incision to promote clotting. With this system, blood glucose 
levels were recorded accurately within 45 seconds.  
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3.3.5. Plasma Sample Collection 
 Animals were killed cutting the heart under anesthesia with thiopental sodium 
(100 mg/Kg, i.p.). Blood samples were subsequently collected from the dead animals in 
tubes containing 15% ethylene diaminetetraacetic acid (EDTA). A 5 ml sample of 
combined arterial and venous blood was easily obtained by this method. These samples 
were then centrifuged at 2000 x g, 10 min at 4ºC. Aliquots (100 μl) of the supernatant 
plasma were stored at -70ºC. 
 
3.3.6. Assay for Plasma Insulin Levels 
 Plasma insulin concentrations were measured from frozen 100 μl aliquots using a 
commercially available RIA kit based on the competition between unlabeled insulin and 
a fixed quantity of [125I]-labeled human insulin for a limited number of binding sites on 
an insulin antibody. Using fixed amounts of antibody and radioactive ligand, the amount 
of added non-radioactive ligand is inversely proportional to the concentration of 
radioactive ligand bound by the antibody. All reagents (standard, antiserum, and [125I] 
insulin radiotracer) were diluted with assay buffer (0.052 mol/L phosphate buffer, pH 
7.5, containing 0.1% sodium azide). Both the antiserum and radiotracer were then 
combined with the insulin samples and standards, vortexed, and allowed to incubate for 
4hr at room temperature. After this, the Amerlex-M second antibody reagent (which 
contains second antibody that is bound to polymer particles) was added to the antibody 
bound to insulin, vortexed, and allowed to incubate at room temperature for a further 10 
min. Separation of the antibody bound fraction was then performed by centrifugation 
(1500 x g, 10 min, 3ºC) followed by decantation of the supernatant by inversion of the 
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tubes in decantation racks and draining for 5 min. Radioactivity (cpm) in the pellet from 
each sample was then counted for a period of 60 seconds in a gamma-counter. This 
enabeled the amount of labeled insulin in the bound fraction to be calculated. Non-
specific binding was first subtracted from all counts. The amount bound for each 
standard was then plotted against insulin concentration on a standard curve. The 
concentration of unlabeled insulin in the sample was then determined by interpolation 
from this standard curve. The assay was completely cross-reactive with insulin from a 
variety of species including rat and human. The sensitivity was 48 pg/ml. 
 
3.3.7. Assay for Plasma Ghrelin Levels 
 Ghrelin concentrations were measured from plasma samples kept at -70ºC using 
a commercial RIA kit, which uses 125I-labeled ghrelin as a tracer molecule. The principle 
of the assay is the same as the one described for plasma insulin measurement. The assay 
is based on the competition of 125I-ghrelin and ghrelin (either standard or sample) 
binding to the limited quantity of antibodies specific for the peptide in each reaction 
mixture. As the quantity of standard or unknown sample in the reaction increases, the 
amount of 125I-ghrelin able to bind to the antibody decreases. The samples, as well as 
standards, were re-suspended in the assay buffer and assayed at 100 μl/sample in 
duplicates. Diluted samples or standard peptide solutions (100 μl) were incubated for 24 
hr with 100 μl of antiserum diluent. A tracer solution (100 μl) was added, and the 
mixture was incubated for another 24 hr. The bound and free ligands were separated 
using a second antibody (200 μl). All the procedures were performed at 4ºC. 500 μl of 
RIA buffer was added and the samples and standards were centrifuged at 1700 x g for 20 
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min at 4ºC. The supernatant was aspirated off and the amount of radioactivity (cpm) in 
the pellet for each standard and sample was counted, for a period of 60 seconds, using a 
gamma-counter. By measuring the amount of 125I-ghrelin bound as a function of the 
concentration of the peptide in standard reaction mixtures, it is possible to construct a 
standard curve, from which the concentrations of peptide in unknown samples can be 
determined, as described for plasma insulin measurement.   
 
3.3.8. Statistical Analysis  
 CR curves as well as responses to a single dose of agonists were analyzed 
individually. The results (mean ± S.E.M.) were expressed as a percentage of the 
maximal vasodilatation (Emax) of PE-evoked vasoconstrictions. The potencies of ghrelin-
, des-acyl ghrelin-, ACh-, and synthetic non-peptide agonists-induced vasodilatation 
were expressed as the concentrations required for half-maximal vasodilatation (EC50) 
evoked by each agonist. Plasma insulin and ghrelin levels were also analyzed 
individually and the results were expressed as pmol/L for plasma insulin and pg/ml for 
plasma ghrelin. Comparison of mean values amongst various groups was performed by 
analysis of variance (ANOVA, Superanova program-SAS Institute, San Francisco, CA). 
Simultaneous multiple comparisons were examined by Scheffe’s F-test. Level of 
significance was set at p<0.05.      
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4. RESULTS 
4.1. Ghrelin and Des-acyl Ghrelin Evoked Vasodilatation in Mesenteric 
Arteries Compared to ACh. 
4.1.1. Ghrelin Evoked Concentration-Dependent Vasodilatation in 
MVB Compared to ACh 
 After one hr of equilibration of MVB ex vivo, the mean ± S.E.M. basal PP values 
under control conditions averaged 15.0 ± 1.2 mmHg in SD rats. PE (80 μmol/L) evoked 
a sustained tonic steady-state contraction in all MVBs after three minutes of perfusion. 
In MVBs, the PP after contraction with PE averaged 120 ± 2.5 mmHg. Cumulative 
concentration-response (CR) curves for ghrelin (100 fmol/L-100 nmol/L) and ACh (10 
pmol/L-10 μmol/L) in PE-contracted MVB demonstrated concentration-dependent 
decreases in PP. A representative experiment comparing the CR patterns between 
ghrelin and ACh to increasing concentrations of ghrelin and ACh is shown in Figure 5A 
and 5B. The maximal vasodilator response (Emax) to ghrelin (45 ± 5% attained at 1 
nmol/L) was much lower (2 fold; p<0.01) than the response evoked by ACh (90 ± 6% 
attained at 1 μmol/L). The addition of ACh to the perfusion medium led to almost 
complete relaxation of MVB (Figures 5B and 6B). The data from several CR curves, 
however, revealed that ghrelin is more potent (EC50 55 ± 6 pmol/L; Emax 45 ± 5%) than 
ACh (EC50 3 ± 2 nmol/L; Emax 90 ± 6%). The differences in mean ± S.E.M. for both 
EC50 and Emax values between ghrelin and ACh are significant (P<0.01), and the data are 
shown in Table 3.  
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 The order in which ghrelin and ACh were used in the same preparation, did not 
affect the responses to either agonist. The time course of ghrelin-evoked vasodilator 
responses, however, was relatively slower in onset (between 20-30 seconds after the 
addition of the peptide), and took a relatively longer time to reach the maximal effect (2-
3 minutes). This is while ACh-evoked responses were relatively much more rapid 
(approximately 10 seconds after the addition of the muscarinic agonist, and 20 seconds 
to reach the plateau) (Figure 6A and 6B). It is noteworthy to mention that the responses 
to ghrelin could be reproduced in the same preparation as long as the concentration of 
the peptide did not exceed 1 nmol/L. This allowed the repeated administration, and 
therefore determination of the responses to ghrelin in the same preparation. 
 
4.1.2. Ghrelin Evoked Endothelium-Dependent Vasodilatation in MVB 
Compared to ACh 
 To evaluate whether the concentration-dependent decreases in PP evoked by 
increasing concentrations of either ghrelin or ACh are endothelium-dependent, 
endothelium was removed by injection of 10 ml air at 5 minute intervals for a maximum 
period of 1 hr. Ghrelin- and ACh-evoked vasodilator responses were then evaluated in 
parallel in both endothelium-intact (Endo +) or endothelium-denuded (Endo -) 
preparations. Ghrelin, at concentrations of 10 pmol/L-1 nmol/L, evoked concentration-
dependent decreases in PP in PE-constricted MVBs (Figure 7A). ACh, at concentrations 
of 10 nmol/L-1 μmol/L, also induced concentration-dependent decreases in PP in PE-
constricted MVBs. In comparison to ghrelin, addition of ACh (1 µmol/L) led to almost 
complete relaxation of MVB (90%, Figure 7B). 
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Figure 5. A) ghrelin, and B) ACh induce reduction of PP (mmHg) in PE (80 μmol/L)-
constricted MVB in a dose-dependent manner. 
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Figure 6. A) Ghrelin (1 nmol/L), and B) ACh (1 μmol/L) induce maximal reduction 
of PP (mmHg) in PE (80 μmol/L)-constricted MVB.  
P
E
Pe
rf
us
io
n 
Pr
es
su
re
 (m
m
H
g)
 
Ghrelin (1 nmol/L) ACh (1 μmol/L) 
A) B)
59
 
Denudation of endothelium led to an increase in basal PP as well as an increase 
in the vasoconstor response to a submaximal dose of PE (80 µmol/L). The basal PP 
increased to 24.0 ± 0.7 mmHg in endothelium-denuded preparations compared to the 
level seen in endothelium-intact preparations (15.0 ± 1.2 mmHg). However, the 
difference in basal PP between endothelium-intact and endothelium-denuded 
preparations did not reach statistical significance. PE-induced increases in PP were 
significantly higher in endothelium-denuded (163 ± 8 mmHg) compared to endothelium-
intact (120 ± 3 mmHg) preparations (p<0.05; Figure 7). Endothelium-removal 
completely abolished the vasodilator responses to increasing concentrations of both 
ghrelin (10 pmol/L-1 nmol/L) and ACh (10 nmol/L-1 μmol/L) (Figure 7A and 7B). 
While vasodilator responses to ghrelin and ACh were not seen in endothelium-denuded 
preparations, addition of sodium nitroprusside (SNP, 100 µmol/L) led to a remarkable 
degree of vasodilatation in both endothelium-intact as well as endothelium-denuded 
preparations to a similar extent (>95%) confirming that removal of endothelium did not 
affect VSM sensitivity to SNP, a directly acting vasodilator agonist. A representative 
experiment demonstrating vasodilator responses to SNP in parallel endothelium-intact 
and -denuded preparations is shown in Figure 8.  
 
 Concentration-dependent decreases in PP in response to increasing 
concentrations of both ghrelin (100 fmol/L-100 nmol/L) and ACh (1 pmol/L- 10 
μmol/L) in endothelium-intact and -denuded preparations were also measured as a 
percentage of maximal PE (80 μmol/L)-induced contractions (Figure 9A and 9B). As 
explained before, whereas both ghrelin (EC50 55 ± 6 pmol/L; Emax 45 ± 5% at 1 nmol/L) 
and ACh (EC50 3 ± 2 nmol/L; Emax 90 ± 6% at 1μmol/L) evoked concentration-
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dependent vasodilatation of MVB in endothelium-intact preparations, increasing 
concentrations of either ghrelin or ACh failed to evoke vasodilatation in endothelium-
denuded preparations. 
 
4.1.3. Effects of L-NAME on Vasodilator Responses to Ghrelin in MVB 
Compared to ACh 
 As the vasodilator responses evoked by ghrelin and ACh were shown to be 
endothemium-dependent, detailed experiments were performed to determine the relative 
contributions of endothelium-derived relaxing factors NO, EDHF, and PGI2 to both 
ghrelin- and ACh-evoked vasodilator responses in perfused MVB. To investigate the 
role of NO, studies were performed in the presence or the absence of L-NAME in the 
perfusion medium and the data is presented in Figure 10A and 10B. Ghrelin, at 
concentration range of 100 fmol/L-100 nmol/L, caused concentration-dependent 
vasodilatation of PE-constricted perfused MVB with an EC50 value of 55 ± 6 pmol/L 
and an Emax value of 45 ± 5% obtained at a concentration of 1 nmol/L. Increasing the 
concentration of ghrelin to 10 and 100 nmol/L did not evoke further relaxation. The 
presence of L-NAME (100 μmol/L) alone in the perfusion buffer for 15 minutes did not 
affect the basal PP, but after addition of PE (80 μmol/L), the PP was increased 
significantly (p<0.05) compared to PP attained with the addition of PE alone (from 120 
± 2.5 mmHg in PE alone compared to 154 ± 6.1 mmHg in PE + L-NAME). However, 
inclusion of a high concentration of L-NAME (100 μmol/L) failed to affect the 
vasodilator responses to increasing concentrations of ghrelin in PE-precontracted MVB 
(Figure 10A).  
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Figure 7. A) Ghrelin, and B) ACh evoke reduction of PP (mmHg) in PE (80 μmol/L)-
constricted MVB in an endothelium-dependent manner. 
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Figure 8. Reduction of PP (mmHg) in PE (80 μmol/L)-constricted MVB in response to 
SNP (100 μmol/L) in the presence and absence of endothelium. 
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Figure 9. Comparison of CR curves to A) ghrelin and B) ACh in PE-constricted MVB 
preparations with or without endothelium. Relaxations were measured as a percentage of 
maximal PE (80 μmol/L)-induced constrictions. Each data point is a mean ± S.E.M. of 6 
different determinations. (* p<0.01 Endo (-) v/s the respective Endo (+) group). 
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Similar to ghrelin, ACh (1 pmol/L-10 μmol/L) also produced a concentration-
dependent vasodilatation in PE-constricted MVBs with EC50 of 3 ± 2 nmol/L and Emax 
value of 90 ± 6% obtained at 1 μmol/L. Increasing the concentration of ACh to 10 
μmol/L did not evoke further vasodilatation. Maximal vasodilatation to ACh was 
significantly different than ghrelin (90 ± 6% for ACh compared to 45 ± 5% for ghrelin, 
p<0.01). Ghrelin, however, produced its half maximal effect (EC50) at much lower 
concentrations than ACh (EC50 3 ± 2 nmol/L for ACh compared to 55 ± 6 pmol/L; 
p<0.01). Presence of L-NAME (100 μmol/L) caused a significant (p<0.05) rightward 
shift in the CR curve to ACh (control EC50 of 3 ± 2 nmol/L compared to L-NAME 
treated EC50 of 9 ± 3 nmol/L). This was also accompanied by a significant (p<0.05) 
reduction in the Emax to ACh in PE-constricted MVBs (Emax 90 ± 6% for ACh compared 
to 75 ± 6% for ACh in the presence of L-NAME). 
 
4.1.4. Effects of TBA on Vasodilator Responses to Ghrelin in the 
Presence and Absence of L-NAME in MVB Compared to ACh 
 Since vasodilator responses evoked by ghrelin were insensitive to the blockade 
by L-NAME, the effect of other distinct mediators of vasodilatation was considered. 
Several experiments were designed to evaluate the involvement of EDHF in ghrelin- and 
ACh-evoked vasodilator responses in PE-constricted MVBs. Figure 10 demonstrates the 
vasodilator responses to ghrelin and ACh in PE-constricted MVBs in the presence and 
absence of TBA (0.5 mmol/L). Inclusion of TBA, a non-selective KCa channel inhibitor, 
in the perfusion medium did not significantly alter either the basal PP or the maximal  
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Figure 10. Comparison of CR curves to A) ghrelin and B) ACh in PE-constricted 
MVB in the presence and absence of NOS inhibitor, L-NAME (100 μmol/L). 
Relaxations were measured as a percentage of maximal PE (80 μmol/L)-induced 
constrictions. Each data point is a mean ± S.E.M. of 6 different determinations. (* 
p<0.01 L-NAME v/s control). 
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vasoconstrictor response to PE (80 µmol/L). Ghrelin-induced vasodilatation (100 
fmol/L-100 nmol/L) was completely abolished in the presence of TBA (Figure 11A). 
The inclusion of L-NAME and TBA together did not affect ghrelin-induced relaxation 
compared to the presence of TBA alone (Figure 12A).  
 
ACh-induced maximal vasodilatation of MVB was significantly (p<0.01) higher 
than that induced by ghrelin (90 ± 6% for ACh compared to 45 ± 5% for ghrelin). 
However, ACh was 54.5 fold less potent compared to ghrelin (EC50 3 ± 2 nmol/L for 
ACh compared to 55 ± 6 pmol/L for ghrelin). In the presence of TBA, the CR curve to 
ACh was significantly (p<0.01) shifted to the right (EC50 3 ± 2 nmol/L in control versus 
30 ± 4 nmol/L in the presence of TBA), with a significant (p<0.05) reduction in the 
maximal relaxation (90 ± 6% in control versus 78 ± 6% in the presence of TBA; Figure 
11B, Table 3). When TBA was added in combination with L-NAME (100 μmol/L) 
together, there was a significant (p<0.01) rightward shift in the CR curve to ACh (EC50 3 
± 2 nmol/L in control versus 100 ± 6 nmol/L in the presence of TBA + L-NAME). This 
was accompanied by a significant (p<0.01) reduction in the maximal vasodilator 
response (Emax 90 ± 6% in control versus 20 ± 7% in the presence of TBA + L-NAME; 
Figure 12B). It is noteworthy to mention that the rightward shift in the CR curve to ACh 
in PE-constricted MVB in the presence of TBA alone was increased by 3.3 fold 
compared to the shift in the presence of L-NAME alone (30 ± 4 nmol/L for TBA 
compared to 9 ± 3 nmol/L for L-NAME, Table 3).  
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Figure 11. Comparison of CR curves to A) ghrelin and B) ACh in PE-constricted MVB in 
the presence and absence of a non-selective Kca channel inhibitor, TBA (0.5 mmol/L). 
Relaxations were measured as a percentage of maximal PE (80μmol/L)-induced 
constrictions. Each data point is a mean ± S.E.M. of 6 different determinations. (* p<0.01 
TBA v/s control group). 
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Figure 12. Comparison of CR curves to A) ghrelin and B) ACh in PE-constricted MVB 
in the presence or absence of a combination of NOS inhibitor (L-NAME, 100 μmol/L)) 
and a non-selective Kca channel blocker (TBA, 0.5 mmol/L). Relaxations were measured 
as a percentage of maximal PE (80μmol/L)-induced constrictions. Each data point ia a 
mean ± S.E.M. of 6 different determinations. (* p<0.01 TBA + L-NAME v/s control 
group). 
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4.1.5. Effects of High Extracellular K+ Concentration on Vasodilator 
Responses to Ghrelin in MVB Compared to ACh 
 The vasodilator responses to ghrelin and ACh were determined either in the 
presence or the absence of high K+ (80 mmol/L)-containing depolarizing Krebs buffer. 
The PP in high K+ (80 mmol/L)-containing buffer measured up to 91.3 ± 4 mmHg. 
Increasing ghrelin concentrations from 100 fmol/L to 100 nmol/L failed to evoke 
vasodilator responses in K+-contracted MVB (Figure 13A). It was not possible to 
determine the EC50 value, but the Emax value for ghrelin-evoked vasodilatation was 9 ±  
3% in the presence of 80 mmol/L K+ compared to the dilator response of 45 ± 5% seen 
in PE-constricted preparations. The ACh-evoked vasodilator responses (EC50; Emax) 
were also significantly lower in high K+ (80 mmol/L)-containing depolarizing buffer 
compared to the responses to ACh seen in PE-constricted MVB preparations with intact-
endothelium. ACh-induced vasodilator responses measured an EC50 value of 3 ± 2 
nmol/L in the presence of PE compared to 30 ± 5 nmol/L in the presence of 80 mmol/L 
[K+].  In addition, the Emax value for ACh-evoked dilatation was 50 ± 5% in the presence 
of 80 mmol/L K+ compared to the dilator response of 90 ± 6% seen in PE-constricted 
preparations (Figure 13B, Table 3).  
 
4.1.6. Effects of Different Specific K+ Channel Blockers on Vasodilator 
Activities of Ghrelin in MVB Compared to ACh 
 Vasodilator responses to 1 nmol/L ghrelin and 1 μmol/L ACh were also 
examined in the presence and absence of different inhibitors of NO, PGI2, and EDHF 
pathways. A ghrelin concentration of 1nmol/L and an ACh concentration of 1 μmol/L 
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were shown by previous experiments in our study to produce maximal vasodilatation in 
PE-constricted MVB. Under control conditions, 1 nmol/L ghrelin evoked 45 ± 5% 
vasodilatation in perfused PE-constricted MVB. This was significantly (p<0.01) 
different from 90 ± 6% vasodilatation evoked by 1 μmol/L ACh (Figure 14, Table 3). 
Inclusion of L-NAME (100 μmol/L) in the perfusion buffer containing PE, failed to 
affect the maximal response evoked by ghrelin (48 ± 6% in the presence of L-NAME 
versus 45 ± 5% in control) (Figure 14, Table 3). Emax to ACh was significantly (p<0.05, 
1.2 fold) reduced in the presence of L-NAME (75 ± 6% in the presence of L-NAME 
versus 90 ± 6% in control). Treatment with the COX inhibitor indomethacin (10 μmol/L) 
produced similar degree of vasodilatations to both ghrelin and ACh compared to their 
respective values under control conditions (40 ± 4% in the presence of indomethacin 
versus 45 ± 5% in control for ghrelin, 81 ± 5% in the presence of indomethacin versus 
90 ± 6% in control for ACh). In the presence of TBA alone, there was a significant 
(p<0.01) reduction in the maximal relaxation to ghrelin (5 ± 0% in the presence of TBA 
versus 45 ± 5% in control) (Figure 14, Table 3). TBA in combination with L-NAME 
failed to have any further effect on maximal vasodilator responses to ghrelin (5 ± 2% in 
the presence of TBA + L-NAME versus 5 ± 0% in the presence of TBA alone). Maximal 
vasodilator responses to ACh were also significantly (p<0.05) reduced in the presence of 
TBA alone (78 ± 5% in the presence of TBA versus 90 ± 6% in control). However, 
when TBA was added in combination with L-NAME, there was a further significant 
(p<0.01) decrease in maximum vasodilator response to ACh (20 ± 7% in the presence of 
TBA + L-NAME versus 78 ± 5% in the presence of TBA alone, and 90 ± 6% in 
control).  
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Figure 13. Comparison of CR curves to A) ghrelin and B) ACh in constricted MVB in 
the presence of either PE or KCl (80 mmol/L). Relaxations were measured as a 
percentage of maximal PE (80 μmol/L)-induced constrictions. Each data point is a 
mean ± S.E.M. of 6 different determinations. (* p<0.01 KCl v/s PE preparations).  
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Apamin is a selective blocker of SKCa channels and ChTX is a non-selective 
blocker of IKCa, BKCa, and some voltage-dependent K+ channels. The maximal 
vasodilatation evoked by ghrelin was significantly (p<0.01) reduced in the presence of 
apamin + ChTX (10 ± 4 % in the presence of apamin + ChTX versus 45 ± 5% in 
control). Similarly, ACh-evoked vasodilatation was also significantly (p<0.05) lower in 
the presence of apamin + ChTX (73 ± 5 % in the presence of apamin + ChTX versus 90 
± 6% in control). The decrease in ghrelin-evoked vasodilator responses in the presence 
of apamin + ChTX was much higher compared to the blockade of ACh-evoked 
vasodilator responses (Figure 14). To assess the effect of endothelial IKCa channels 
specifically, an experiment was designed to perform ghrelin- and ACh-evoked maximal 
vasodilator responses in the combined presence of apamin (1 μmol/L) and TRAM-34 (a 
selective IKCa channel blocker, 10 μmol/L). A combination of apamin + TRAM-34 
resulted in significant reductions in both ghrelin- and ACh-evoked maximal 
vasodilatation (ghrelin: 2 ± 0% in the presence of apamin + TRAM-34 versus 45 ± 5% 
in control [p<0.01], ACh: 68 ± 6% in the presence of apamin + TRAM-34 versus 90 ± 
6% in control [p<0.05]) (Figure 14). The decrease in ghrelin-evoked vasodilator 
responses in the presence of apamin + TRAM-34 was higher than that in ACh-evoked 
vasodilator responses in MVB (43% decrease for ghrelin versus 22% decrease for ACh; 
Figure 14). Ghrelin-evoked maximal vasodilator responses were reduced more in the 
presence of apamin + TRAM-34 than in the presence of apamin + ChTX; a combination 
of apamin + TRAM-34 resulted in almost a complete abolition of ghrelin-evoked 
responses (45 ± 5% in control versus 10 ± 4% in the presence of apamin + ChTX, and 2 
± 0% in the presence of apamin + TRAM-34). 
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 To evaluate the involvement of EDHF in ghrelin- and ACh-evoked 
vasodilatations in MVB in more detail, our study was to assess ghrelin- and ACh-
induced maximal vasodilatations in the presence of ouabain (10 μmol/L) and Ba2+ (30 
mmol/L) (Figure 14). Ouabain is an inhibitor of Na+/K+-ATPase pump and Ba2+ is a 
blocker of Kir channels. Treatment with ouabain + Ba2+ diminished ghrelin-evoked 
maximal vasodilatations significantly (p<0.01; 13 ± 5% in the presence of ouabain + 
Ba2+ versus 45 ± 5% in control). Similarly, ACh-evoked maximal vasodilatations were 
significantly (p<0.01) reduced in the presence of ouabain + Ba2+ (52 ± 6% in the 
presence of ouabain + Ba2+ versus 90 ± 6% in control). However, the decrease in 
ghrelin-evoked responses in the presence of ouabain + Ba2+ was not significantly 
different from that of ACh (32% decrease in ghrelin-evoked response versus 38% 
decrease in ACh-evoked response).  
 
To validate the minimal involvement of KATP channels in EDHF-mediated 
pathways, an experiment was performed to assess ghrelin- and ACh-induced maximal 
vasodilatation in the presence of glibenclamide (10 μmol/L), a specific blocker of KATP 
channels. Unlike apamin + ChTX and apamin + TRAM-34, inclusion of glibenclamide 
in the perfusion medium caused no inhibition of ghrelin-mediated maximal response in 
PE-constricted MVB (40 ± 5 in the presence of glibenclamide versus 45 ± 5% in 
control) (Figure 14). In contrast, maximal vasodilatation to ACh was significantly 
(p<0.05) attenuated in the presence of glibenclamide (70 ± 4% in the presence of 
glibenclamide versus 90 ± 6% in control). However, it is noteworthy to mention that the 
decrease in ACh-evoked maximal vasodilatation in the presence of glibenclamide was to 
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the same extent as that in the presence of L-NAME (20% in the presence of 
glibenclamide versus 15% in the presence of L-NAME). 
 
4.1.7. Des-acyl Ghrelin Evokes Concentration-Dependent 
Vasodilatation in MVB in an Endothelium-Dependent Manner 
 After 1hr equilibration, the basal PP values under control conditions averaged 15 
± 1.2 mmHg. Three minutes of perfusion with PE (80 μmol/L) resulted in a sustained 
tonic steady-state contraction of 120 ± 2.5 mmHg in MVB. Cumulative CR curves for 
des-acyl ghrelin (100 fmol/L-100 nmol/L) in PE-constricted MVB demonstrated 
concentration-dependent decreases in PP. A representative experiment demonstrating 
CR patterns to increasing concentrations of des-acyl ghrelin is shown in Figure 15A. 
The CR curve pattern to des-acyl ghrelin (100 fmol/L-100 nmol/L) was closely similar 
to the CR curve to ghrelin with similar Emax values (Emax values of 45 ± 5% for ghrelin 
and 43 ± 6% for des-acyl ghrelin). The Emax values for both peptides were reached at the 
same concentration level (1 nmol/L) (Figure 16A and 16B). In addition, the data from 
several CR curves confirmed that the EC50 values for ghrelin and des-acyl ghrelin were 
also closely similar (EC50 49 ± 7 pmol/L for des-acyl ghrelin and EC50 55 ± 6 pmol/L for 
ghrelin). The time-course of des-acyl ghrelin-evoked vasodilator responses also 
followed the same pattern as ghrelin with a “slower onset” and a relatively “longer time” 
to reach maximal effect compared to the other agonist ACh, which was much more 
rapid.  
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Figure 14. Ghrelin (1 nmol/L) and ACh (1 μmol/L)-evoked maximal relaxations of PE (80 μmol/L)-constricted MVB in the presence 
of NOS inhibitor (L-NAME, 100 μmol/L), non-selective KCa channel blocker (TBA, 0.5 mmol/L), a combination of L-NAME + TBA, 
a combination of selective SKCa channel blocker (apamin, 1 μmol/L) and a non-selective blocker of BKCa and IKCa (charybdotoxin 
ChTX, 100 nmolL), a combination of apamin and a selective blocker of IKCa (TRAM-34, 10 μmol/L), KATP channel blocker 
(glibenclamide, 10μmol/L), a combination of Na+/K+-ATPase pump inhibitor (ouabain, 10 μmol/L) and Kir channel blocker (Ba2+, 30 
mmol/L), and COX inhibitor (indomethacin, 10 μmol/L). Relaxations were measured as a percentage of maximal PE-induced 
contractions. Each data point is a mean±S.E.M. of 6 different preparations (* p<0.05 and ** p<0.01 v/s control group).   
■ Ghrelin □ ACh 
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Table 3. EC50 and Emax values for Ghrelin- and ACh-evoked relaxations of MVB in the 
presence or absence of endothelium, as well as in pretreated preparations with NOS 
inhibitor (L-NAME, 100 μmol/L), non-selective Kca channel blocker (TBA, 0.5 mmol/L), 
a comnination of L-NAME + TBA, and a depolarizing agent KCl (80 mmol/L). 
* p<0.05, ** p<0.01 endothelium-denuded or different inhibitors v/s the respective 
control group. 
§§ p<0.01 control ghrelin v/s control ACh.  
 
 
 
 
 
 
Ghrelin ACh 
Group 
EC50 (pM) Emax EC50 (nM) Emax 
Control 55±6 45±5 3±2§§ 90±6§§ 
Endo (-) ------- 4±0** ------- 7±8** 
L-NAME 55±2 48±6 9±3* 75±6* 
TBA ------- 5±0** 30±4** 78±5* 
TBA + L-NAME ------- 5±2** 100±6** 20±5** 
KCl ------- 9±3** 30±5** 50±5** 
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The importance of endothelium in the regulation of vascular tone by increasing  
concentrations of des-acyl ghrelin was also demonstrated. In comparison to the intact-
endothelium, endothelium denudation increased both basal PP and PP after contraction 
with PE (80 μmol/L). Basal PPs of 15 ± 1.2 mmHg in intact-endothelium preparations 
were increased to 24 ± 0.7 mmHg in endothelium-denuded preparations. PE-evoked 
contractions of 120 ± 2.5 mmHg in endothelium-intact preparations were increased to 
163 ± 8 mmHg in endothelium-denuded preparations. Similar to ghrelin, endothelium-
denudation completely abolished vasodilator responses to increasing concentrations of 
des-acyl ghrelin (100 fmol/L-100 nmol/L) (Figure 15A and 15B). 
 
4.2. Ghrelin Evokes Vasodilatation in the MVB in the Presence of 
Antagonists of GHSR1a receptors 
4.2.1. [D-Lys3]-GHRP-6, a competitive Antagonist of GHSR-1a 
Receptors, Evokes Vasodilatation in MVB 
 In order to determine the involvement of GHSR-1a receptors in ghrelin- and des-
acyl ghrelin-evoked vasodilatations, an experiment was designed to assess ghrelin- and 
des-acyl ghrelin-evoked vasodilatation of MVB in the presence of [D-Lys3]-GHRP-6, a 
competitive antagonist of the classical GHSR-1a receptors. A representative tracing of a 
single experiment is shown in Figure 17. Basal PP in MVB averaged 15 ± 1.2 mmHg. 
PE (80 μmol/L) induced increases in PP up to 120 ± 2.5 mmHg. Addition of a high 
concentration (10 μmol/L) of [D-Lys3]-GHRP-6 per se evoked decreases in PP in PE-
constricted MVBs, which were not statistically different from those induced by ghrelin 
(Emax 45 ± 5% for ghrelin and 37 ± 4% for [D-Lys3]-GHRP-6).  
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Figure 15. Des-acyl ghrelin induces reduction of PP (mmHg) in PE (80 μmol/L)-
constricted MVB in an endothelilum-dependent manner: A) Preparation with 
intact-endothelium, B) Preparation with denuded-endothelium.  
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Figure 16. A) Des-acyl ghrelin (1 nmol/L), and B) ghrelin (1 nmol/L) induce 
maximal reduction of PP (mmHg) in PE (80 μmol/L)-constricted MVB.  
Pe
rf
us
io
n 
Pr
es
su
re
 (m
m
H
g)
 
Ghrelin (1 nmol/L) Des-acyl ghrelin (1 nmol/L) 
A
)
B
)
80
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pe
rf
us
io
n 
Pr
es
su
re
 (m
m
H
g)
 
[D-Lys3]-GHRP-6 (10 nmol/L) 
Figure 17. [D-Lys3]-GHRP-6, an antagonist of GHSR-1a receptors, reduces PP 
(mmHg) in PE (80 μmol/L)-constricted MVB. 
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4.2.2. L-756867, a Peptide Antagonist of GHSR-1a receptors, does not 
Block Ghrelin-Evoked Vasodilator Responses in MVB  
 Different antagonists of the classical GHSR-1a receptors may have different 
structural and chemical properties, and therefore may influence the receptor and both the 
potency and efficacy of ghrelin signaling in different manners. Vasodilatation in 
response to ghrelin was also evaluated in the presence of L-756867, a peptide antagonist 
of the classical GHSR-1a receptors. Inclusion of L-756867 in the perfusion buffer, up to 
a concentration of 1 μmol/L, failed to alter the basal PP or evoke any vasodilator 
response (Figure 18A). Moreover, L-756867 (1 μmol/L) failed to affect the vasodilator 
responses evoked by ghrelin. Similar to the control conditions (absence of the 
antagonist), where ghrelin induced maximal vasodilatation of Emax 45 ± 5%, ghrelin 
evoked maximal vasodilatation of Emax 42 ± 3% in MVBs treated with antagonist 
(Figures 18B and 18C). 
 
4.3. Non-Peptide Agonists of GHSR-1a receptors, L-166446 and L-
163255, Evoke Concentration-Dependent Vasodilatation in MVB 
 Similar to ghrelin, synthetic peptidyl GHSs have also been demonstrated to exert 
direct and GH-independent cardiac actions (Locatelli et al., 1999; Imazio et al., 2002). 
However, to our knowledge, there has not been any study performed investigating 
cardiovascular actions of synthetic non-peptidyl GHSs. Therefore, based on the above 
information, our purpose was to investigate if the two synthetic non-peptidyl agonists of 
GHSR1a, L-166446 and L-163255, can promote vasodilator responses in constricted 
MVBs. Cumulative CR curves for both non-peptide agonists L-166446 and L-163255  
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Figure 18. L-756867 (1 μmol/L), an antagonist of GHSR-1a receptors, A) does not 
induce reduction in PP (mmHg), and B) does not block ghrelin (1 nmol/L)-evoked 
reduction in PP in PE (80 μmol/L)-constricted MVBs. C) Reductions in PP by 
ghrelin in the presence and absence of L-756867 were also measured as 
percentages of maximal PE-induced contractions. Results are mean ± S.E.M. of 5 
different determinations.  
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(100 fmol/L-100 nmol/L) in PE-constricted MVBs demonstrated concentration-
dependent decreases in PP. Representative experiments demonstrating CR patterns to 
increasing concentrations of L-166446 and L-163255 are shown in Figure 19A and 19B. 
Both L-166446- and L-163255-evoked concentration-dependent decreases in PP were 
also measured as a percentage of maximal PE-induced contractions (Figure 21). Similar 
to ghrelin, both compounds reached their maximal effects at the concentration of 1 
nmol/L. However, the maximal vasodilatation in response to L-166446 (Emax 70 ± 6%, 
1.6 fold, p<0.01) and L-163255 (Emax 60 ± 5%, 1.3 fold, p<0.05) were significantly 
higher than the response evoked by ghrelin (Emax 45 ± 5%) (Figure 19A and 19B, Figure 
20A, 20B, and 20C). A comparison of the data from several CR curves for the two non-
peptides demonstrated that L-166446 was more potent (EC50 4 ± 2 pmol/L; Emax 70 ± 
6%) than L-163255 (EC50 6 ± 3 pmol/L; Emax 60 ± 5%). However, the comparison of 
EC50 and Emax values for the two non-peptides did not reach statistical significance 
(Figure 21, Table 4). Both non-peptide agonists were shown to be much more potent 
(p<0.01) compared to ghrelin (EC50 4 ± 2 pmol/L for L-166446, EC50 6 ± 3 pmol/L for 
L-163255, EC50 55 ± 6 pmol/L for ghrelin). A comparison of EC50 and Emax values for 
L-166446, L-163255, and ghrelin is depicted in Table 4. 
 
4.4. Short Peptide Fragments of Des-acyl Ghrelin Evoke Vasodilatation 
in MVB 
 In agreement with the previous data, the present study also showed that the 
whole molecule of ghrelin may not be necessary for its vasodilator response. Des-acyl  
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Figure 19. Agonists of GHSR-1a receptors A) L-166446 (100 fmol/L-100 
nmol/L), and B) L-163255 (100 fmol/L-100 nmol/L) induce reductions in PP 
(mmHg) in PE (80 μmol/L)-constricted MVBs in a concentration-dependent 
manner. 
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Figure 20. Agonists of GHSR-1a receptor A) L-166446 (1 nmol/L), and B) L-
163255 (1 nmol/L) induce maximal reductions in PP (mmHg) in PE (80 μmol/L)-
constricted MVBs. C) Reductions in PP by the two agonists were also measured as 
percentages of maximal PE-induced contractions. Results are mean ± S.E.M. of 5 
different determinations. * p<0.05 and ** p<0.01 agonists v/s ghrelin. 
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Figure 21. Comparison of CR curves (100 fmol/L-100 nmol/L) for ghrelin, L-
166446, and L-163255 in PE (80 μmol/L)-constricted MVBs. Relaxations were 
measured as percentages of maximal PE-induced contractions at each concentration. 
Each data point is mean ± S.E.M. of 5 different determinations. * p<0.05 and ** 
p<0.01 agonists v/s their respective concentrations of ghrelin. 
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Table 4. EC50 and Emax values for Ghrelin-evoked relaxations of PE (80 μmol/L)-
constricted MVB compared to the relaxations evoked by the two synthetic nonpeptide 
agonists of GHSR-1a receptors, L-166446 and L-163255. 
* p<0.05 and ** p<0.01 synthetic nonpeptide agonists v/s ghrelin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group EC50 (pM) Emax 
Ghrelin                  55±6                 45±5 
L-166446 4±2** 70±6** 
L-163255 6±3** 60±5* 
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ghrelin could dilate MVB to the same extent as ghrelin. Therefore, several fragments of 
des-acyl ghrelin were prepared by successive deletions of C-terminal amino acid 
residues to determine the active core required for des-acyl ghrelin-evoked vasodilatation. 
Vasodilatation or responses to 1 nmol/L concentration of either des-acyl ghrelin or its 
fragments consisting of 20, 16, 10, 6, 4, and 3 amino acids from the N-terminal were 
evaluated in PE (80 μmol/L)-constricted MVBs. A comparison of the vasodilator effects 
of des-acyl ghrelin with other fragmented des-acyl ghrelin peptides is presented in 
Figure 22. Des-acyl ghrelin induced a maximal vasodilatation of Emax 43 ± 6% in PE-
constricted MVBs. All the short peptides encompassing the first 20, 16, 10, 6, 4, and 3 
residues of des-acyl ghrelin were found to evoke vasodilatation about as efficiently as 
the full-length des-acyl ghrelin. Vasodilator responses to a 1 nmol/L concentration of 
single amino acids L-serine or glycine, however, were significantly reduced. While des-
acyl ghrelin produced a maximal vasodilatation of Emax 43 ± 6%, L-serine-, and glycine-
evoked maximal vasodilatation were reduced to 24 ± 4% (p<0.05) and 17 ± 3(p<0.01), 
respectively. A representative tracing demonstrating reductions in PP in constricted 
MVBs in response to 1 nmol/L concentrations of L-serine, glycine, and des-acyl ghrelin 
is demonstrated in Figure 23.  
 
4.5. Ghrelin-Evoked Vasodilatation in MVB in Relation to Plasma 
Ghrelin Levels in STZ-treated Diabetic rats 
4.5.1. Metabolic Parameters in STZ-treated Diabetic rats 
Following an overnight fasting, diabetes was induced in 12 weeks old SD rats by 
 
 
89
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
20
40
60
80
100
28 20 16 10 6 4 3
R
el
ax
at
io
n 
(%
) 
Short Amino Acid Fragments of Des-acyl ghrelin
Figure 22. Maximal Relaxation to short amino acid fragments (1 nmol/L) of des-
acyl ghrelin in PE (80 μmol/L)-constricted MVB. Relaxations were measured as 
percentages of maximal PE-induced contraction. Results are mean ± S.E.M. of 6 
different determinations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 23. Reductions of PP (mmHg) in PE (80 μmol/L)-constricted MVBs in response to single amino acids A) L-serine (1 nmol/L) and 
B) Glycine (1 nmol/L) compared to C) des-acyl ghrelin (1 nmol/L). D) Reductions in PP were also measured as percentages of maximal 
PE-induced contractions. Results are mean ± S.E.M. of 6 different determinations. * p<0.05 and ** p<0.01 single amino acids  v/s des-
acylghrelin. 
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a single i.p. injection of STZ in citrate buffer. Metabolic variables of both STZ-induced 
diabetic and control rats were then evaluated after 4 and 8 weeks of treatment. Table 5  
summarizes metabolic variables of 4- and 8-weeks STZ-induced diabetic and control SD 
rats. There were no differences in weight at the time of STZ-treatment. All rats weighed  
approximately between 360-380 grams at the age of 12 weeks. Control animals, both fed 
and fasted, gained weight after 4 and 8 weeks (after STZ-treatment group versus before 
STZ-treatment group) resulting in significant weight differences at the time of sacrifice 
(Table 5). Weight gain in control fed/fasted animals, however, was more pronounced in 
8-weeks (p<0.01) compared to 4-weeks (p<0.05). Control fed rats weighed 372 ± 5 to 
462 ± 6 after 4 weeks (p<0.05) compared to 380 ± 9 to 511 ± 10 after 8 weeks (p<0.01). 
Similarly, control fasted rats weighed 366 ± 7 to 430 ± 11 after 4 weeks (p<0.05) 
compared to 374 ± 3 to 490 ± 9 after 8 weeks (p<0.01). In contrast to control rats, 
diabetic rats, both fed and fasted, lost weight after 4 and 8 weeks of STZ treatment (after 
STZ-treatment group versus before STZ-treatment group) resulting in significant weight 
reductions at the time of sacrifice (Table 5). Weight loss in diabetic fed/fasted animals, 
was more pronounced in 8-weeks (p<0.01) compared to 4-weeks (p<0.05). Diabetic fed 
rats weighed 365 ± 4 to 330 ± 7 after 4 weeks (p<0.05) compared to 379 ± 6 to 281 ± 24 
after 8 weeks (p<0.01). Similarly, diabetic fasted rats weighed 377 ± 2 to 332 ± 4 after 4 
weeks (p<0.05) compared to 383 ± 9 to 263 ± 15 after 8 weeks (p<0.01). 
 
 Type 1 diabetes is associated with low plasma insulin and high glucose levels 
(Hopfner et al., 1999). Accordingly, the mean blood glucose levels after 4 weeks of  
induced diabetes were significantly higher in both fasted (20.4 ± 0.5 mmol/L) and fed 
(23.1 ± 1.4 mmol/l) rats compared to their age-matched controls (4.2 ± 0.9 and 5.3 ± 0.2 
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mmol/L in fasted and fed animals, respectively) (Table 5). Similarly, blood glucose was 
significantly (p<0.01) elevated in the 8-weeks STZ-diabetic group (25 ± 0.9 and 21.1 ± 
1.2 mmol/L in fed and fasted animals, respectively) relative to the control group (5.2 ± 
0.2 and 4 ± 0.6 mmol/L in fed and fasted animals, respectively) (Table 5). There were no 
significant differences in mean blood glucose values between 4- and 8-weeks fed and 
fasted controls or the 4- and 8-weeks fed and fasted STZ-treated group (Table 5). 
 
4.5.2. Plasma Ghrelin Levels are Increased in Fasted as well as in STZ-
treated Diabetic Rats 
 Plasma ghrelin concentrations (pg/ml) were measured using a commercial radio-
immunoassay kit in 4- and 8-weeks control and diabetic animals. The mean plasma 
ghrelin concentration was 390 ± 10 pg/ml in 4-weeks control fed rats (Figure 24A, Table 
6). Plasma ghrelin level was significantly higher in rats that were fasted overnight (720 ± 
16 pg/ml, p<0.05). Fasting overnight increased plasma ghrelin levels in 4-weeks diabetic 
rats as well. While mean plasma ghrelin concentration was high (583 ± 9 pg/ml) in 
diabetic fed rats, in 4-weeks STZ-induced rats that were fasted the plasma ghrelin level 
was much higher (950 ± 15 pg/ml, p<0.05). Similarly, plasma ghrelin levels were also 
augmented by fasting overnight in 8-weeks control and diabetic animals (Figure 24B, 
Table 6). There were no significant differences in plasma ghrelin concentrations 
between 8-weeks and 4-weeks fed/fasted control rats. The mean plasma ghrelin 
concentrations were 410 ± 7 and 752 ± 10 pg/ml in 8-weeks fed and fasted control rats 
compared to 390 ± 10 and 720 ± 16 pg/ml in 4-weeks fed and fasted control rats (Figure 
93
 
* P<0.05 and ** p<0.01 fed versus fed, fasted versus fasted (control versus control, diabetic versus diabetic, weight before STZ 
treatment versus after STZ treatment). 
§ p<0.05 and §§ p<0.01 fed versus fed, fasted versus fasted (control versus diabetic). 
            Groups 4-weeks diabetics 8-weeks diabetics 
 
Control 
fed 
Control 
fasted 
Diabetic 
fed 
    
   Diabetic 
fasted 
 
Control 
fed 
Control 
fasted 
Diabetic 
fed 
Diabetic 
fasted 
 
Weight before STZ 
treatment 
 
372±5 366±7 365±4 377±2 380±9 374±3 379±6 383±9 
 
Weight after STZ 
treatment 
 
462±6* 430±11* 330±7* 332±4*  511±10**    490±9** 281±24**   263±15** 
 
Glucose (mM) 
 
5.3±0.2 4.2±0.9 23.1±1.4§§ 20.4±0.5§§ 5.2±0.2    4.0±0.6  25±0.9§§  21.1±1.2§§ 
Insulin (pM) 650±73 624±39 104±16§§ 98±13§§ 596±43 555±32 120±11§§ 114±12§§ 
Table 5. Metabolic variables in 4- and 8-weeks STZ-induced diabetic and control SD rats. 
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24A and 24B, Table 6). However, plasma ghrelin concentrations were significantly 
(p<0.05) different between 8- and 4-weeks fed/fasted diabetic rats. Mean plasma ghrelin 
concentration was 806 ± 16 pg/ml in 8-weeks diabetic fed compared to 583 ± 9 pg/ml in 
4-weeks diabetic fed. Moreover, plasma ghrelin concentration was 1220 ± 10 pg/ml in 8-
weeks STZ diabetic rats under fasting state compared to 950 ± 15 pg/ml in 4-weeks 
STZ-diabetic fasted rats (Figure 24A and 24B, Table 6).  
 
 Similar to fasting, diabetes was also shown to increase plasma ghrelin 
concentrations in both fed and fasted animals (Figure 24A and 24B, Table 6). As 
mentioned before, the mean plasma ghrelin concentration was 390 ± 10 pg/ml in 4-
weeks control fed rats. Diabetes for 4 weeks increased plasma ghrelin levels 
significantly (583 ± 9 pg/ml, p<0.05). Additionally, while the mean plasma ghrelin 
concentration was 720 ± 16 pg/ml in control fasted rats, 4 weeks diabetes increased 
plasma ghrelin levels significantly (950 ± 15 pg/ml, p<0.05). Plasma ghrelin levels were 
also increased significantly (p<0.01) after 8 weeks of diabetes in both fed and fasted 
animals. Plasma ghrelin levels were 806 ± 16 pg/ml in diabetic fed rats compared to 410 
± 7 pg/ml in control fed animals. Additionally, plasma ghrelin concentrations were 1220 
± 10 pg/ml in diabetic fasted rats compared to 752 ± 10 pg/ml in control fasted animals. 
Plasma ghrelin levels were significantly (p<0.05) different between 8-weeks and 4-
weeks fed and fasted diabetic animals.  
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Figure 24. Plasma ghrelin concentrations (pg/ml) in fed/fasted control and diabetic SD rats 
after 4- and 8-weeks of STZ treatment. Results are mean ± S.E.M. of 5 different 
experiments. * p<0.05 and ** p<0.01 fed v/s fasted (control v/s control; diabetic v/s 
diabetic). § p<0.05 and §§ p<0.01 fed v/s fed and fasted v/s fasted (control v/s diabetic). # 
p<0.05 and ## p<0.01 fed v/s fed and fasted v/s fasted (control v/s control, diabetic v/s 
diabetic, 4- v/s 8-weeks). 
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4.5.3. Ghrelin-Evoked Vasodilatation in MVB is Diminished in Fasted 
as well as STZ-treated Diabetic Rats 
 Vasodilatation to both ghrelin (1 nmol/L) and ACh (1μmol/L) was measured as a 
percentage of maximal PE (80 μmol/L)-induced contraction. Ghrelin-evoked 
vasodilatation in MVB in 4-weeks control fed animals was 45 ± 12% (Figure 25A). The 
maximal vasodilator responses to ghrelin were significantly lower in overnight fasted 
rats (26 ± 13%) compared to age-matched rats that were maintained in fully fed state. A 
similar phenomenon of reduced (p<0.01) vasodilator response to ghrelin was noticed in 
8-weeks control rats that were subjected to fasting (from 40 ± 15% in control fed to 25 ± 
14% in control fasted). Age of the animals, however, did not have significant effect on 
ghrelin-induced vasodilatation in control rats (Figure 25A and 25B). Ghrelin induced 
vasodilatation in MVB in 8-weeks control fed/fasted rats to almost the same extent as 4-
weeks control fed/fasted animals. A representative tracing comparing ghrelin-evoked 
decreases in PP in MVBs of 8-weeks control fed versus control fasted rats is shown in 
Figure 26. Ghrelin induced vasodilatation of MVB in 4-weeks diabetic fed animals by 
38 ± 15% (Figure 25A). Fasting 4-weeks diabetic animals for an overnight duration, 
significantly (p<0.05) decreased ghrelin-evoked vasodilator effects in MVB to 28 ± 
10%. Similarly, fasting 8-weeks diabetic rats decreased ghrelin-evoked vasodilatations 
in MVB compared to 8-weeks diabetic fed animals (p<0.01; 29 ± 10% in 8-weeks 
diabetic fed versus 13 ± 9% in 8-weeks diabetic fasted).  
 
Diabetes for 4 weeks did not cause any significant reduction in vasodilator 
response to ghrelin (Figure 25A). Ghrelin-induced vasodilatation was 38 ± 15% in 4-
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weeks diabetic fed rats compared to 45 ± 12% in 4-weeks fed controls. Moreover, 
ghrelin-induced vasodilatation was 28 ± 10% in 4-weeks diabetic fasted rats compared 
to 26 ± 13% in 4-weeks fasted controls. Diabetes for 8 weeks, however, induced a very 
significant (p<0.01) reduction in ghrelin-induced vasodilator response (Figure 25B). 
Ghrelin-induced vasodilatation was 29 ± 10% in 8-weeks diabetic fed compared to 40 ± 
15% in 8-weeks fed controls. A representative tracing of one single experiment is shown 
in Figure 27. In addition, ghrelin induced only 13 ± 9% vasodilatation in MVB in 8-
weeks diabetic fasted compared to 25 ± 14% in 8-weeks fasted controls. A 
representative tracing of one single experiment is shown in Figure 28.  
 
Ghrelin-induced vasodilator responses in 8-weeks diabetic (fed/fasted) animals 
were significantly different compared to 4-weeks diabetic (fed/fasted) rats (Figure 25A 
and 25B). While 8-weeks diabetes induced 29 ± 10% vasodilator response to ghrelin in 
diabetic fed rats, the response was 38 ± 15% in 4-weeks diabetic fed rats (p<0.05). 
Additionally, whereas ghrelin induced only 13 ± 9% vasodilatation in diabetic fasted 
animals after 8 weeks of diabetes, the response was 28 ± 10% in 4-weeks diabetic fasted 
rats (p<0.01). The relationship between plasma ghrelin concentrations and its vasodilator 
responses in MVB from 4- and 8-weeks control and diabetic (fed/fasted) rats is 
summarized in Table 6.  
 
 ACh induced vasodilatation of MVB in 4-weeks control fed rats by 98 ± 3% 
(Figure 25A, Table 6). Fasting did not have any effect on ACh-induced relaxation (98 ± 
2%). There were no differences in ACh-evoked vasodilator responses between 4- and 8-
weeks fed/fasted animals (97 ± 3% and 98 ± 2% in 8-weeks control fed and fasted, 
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respectively) (Figure 25B, Table 6). Diabetes significantly (p<0.01) reduced ACh-
induced vasodilatation in 4-weeks diabetic fed (77 ± 6%) compared to 4-weeks control 
fed rats (98 ± 3%). ACh-induced vasodilatation in 4-weeks diabetic fasted rats was also 
attenuated (1.36 fold) to the same extent as diabetic fed rats (1.27 fold) (78 ± 9% in 4-
weeks diabetic fasted compared to 98 ± 2% in 4-weeks control fasted animals, p<0.01). 
The same situation was true for 8-weeks diabetic animals. ACh-induced vasodilatation 
was significantly (p<0.01) reduced to 60 ± 10% in 8-weeks diabetic fed compared to 97 
± 3% in control fed rats. Similarly, the vasodilator response to ACh was significantly 
(p<0.01) attenuated to 65 ± 13% in 8-weeks diabetic fasted compared to 98 ± 2% in 
control fasted rats. It is noteworthy to mention that there was a duration-dependent fall 
in the vasodilator responses to ACh in STZ-diabetic rats as the vasodilatations were 
significantly lower in 8-weeks STZ-diabetic animals compared to 4-weeks (77 ± 6% in 
4-weeks diabetic fed versus 60 ± 10% in 8-weeks diabetic fed, and 78 ± 9% in 4-weeks 
diabetic fasted versus 65 ± 13% in 8-weeks diabetic fasted) (Figure 25A and 25B, Table 
6). There were significant differences between ACh-induced vasodilatation in 4- and 8- 
weeks diabetic fed as well as diabetic fasted rats (p<0.01). A representative tracing of 
one single experiment demonstrating progressive decreases in ACh-evoked 
vasodilatation in MVB of 4- and 8-weeks diabetic fasted rats is shown in Figure 29.  
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Figure 25. Vascular relaxation (%) of PE (80 μmol/L)-constricted MVB in response to 
Ach (1 μmol/L) and ghrelin (1 nmol/L) in fed/fasted control and diabetic SD rats.  
Relaxations were measured as a percentage of maximal PE-induced constractions. Results 
are mean ± S.E.M. of 5 different determinations. * p<0.05 and ** p<0.01 fed v/s fasted 
(control v/s control; diabetic v/s diabetic). § p<0.05 and §§ p<0.01 fed v/s fed and fasted 
v/s fasted (control v/s diabetic). # p<0.05 and ## p<0.01 fed v/s fed and fasted v/s fasted 
(control v/s control, diabetic v/s diabetic, 4- v/s 8- weeks).  
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Figure 26. Reductions in PP (mmHg) in PE (80 μmol/L)-constricted MVB in response 
to ghrelin (1 nmol/L) in 8-weeks A) fed compared to B) fasted control SD rats.  
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Figure 27. Reductions in PP (mmHg) in PE (80 μmol/L)-constricted MVB in 
response to ghrelin (1 nmol/L) in 8-weeks STZ-treated A) control fed compared to B) 
diabetic fed SD rats. 
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Figure 28. Reductions in PP (mmHg) in PE (80 μmol/L)-constricted MVB in 
response to ghrelin (1 nmol/L) in 8-weeks STZ-treated A) control fast compared 
to B) diabetic fast SD rats. 
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ACh (1 μmol/L) 
A) Control fast (4 or 8 weeks)  B) Diabetic fast (4 weeks) C) Diabetic fast (8 weeks)
ACh (1 μmol/L) ACh (1 μmol/L) 
Figure 29. Reductions in PP (mmHg) in PE (80 μmol/L)-constricted MVBs in response to ACh (1 μmol/L) in A) control fast  
(4- or 8-week), B) diabetic fast (4-week), and C) diabetic fast (8-week).   
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* P<0.05 and ** p<0.01 fed versus fasted (control versus control, diabetic versus diabetic). 
§ p<0.05 and §§ p<0.01 fed versus fed, fasted versus fasted (control versus diabetic). 
 # p<0.05 and ## p<0.01 fed versus fed and fasted versus fasted (control versus control, diabetic versus diabetic, 4- versus 8-weeks).  
 
 
 
 
 
Groups 4-weeks diabetes 8-weeks diabetes 
 Plasma ghrelin 
(pg/ml) 
Vascular relaxation (%) 
          Ghr                   ACh 
Plasma ghrelin 
(pg/ml) 
Vascular relaxation (%) 
           Ghr                     ACh 
Control fed 390±10 45±12 98±3 410±7 40±15 97±3 
Control fasted 720±16* 26±13** 98±2 752±10* 25±14** 98±2 
Diabetic fed 583±9§ 38±15 77±6§§ 806±16§§# 29±10§§# 60±10§§## 
Diabetic fasted 950±15*§ 28±10* 78±9§§ 1220±10*§§# 13±9**§§## 65±13§§## 
Table 6. Plasma ghrelin concentrations (pg/ml) and vascular relaxations (%) to ghrelin (1 nmol/L) and acetylcholin (ACh, 1 
μmol/L) in PE (80 μmol/L)-constricted MVBs of 4- and 8-weeks fed/fasted STZ-induced diabetic and control SD rats.  
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5. Discussion 
5.1. Mechanisms Underlying ACh- and Ghrelin-Evoked 
Vasodilatation in MVB 
5.1.1. ACh-Evoked Vasodilatation in MVB is Mediated Mainly 
through both NO and EDHF 
The results of the present study clearly demonstrate that, in the rat MVB, dose-
dependent vasodilatation to the endothelium-dependent muscarinic agonist, ACh, has 
two major components, one of which is L-NAME-sensitive and mediated by NO, 
while the other one is sensitive to TBA, a non-selective KCa channel blocker. On the 
basis of these results, it is likely that the second component of the vasodilatation is 
mediated by putative EDHF. This is in agreement with the conclusions of Adeagbo 
and Triggle (1993), and McCulloch et al. (1997) that both EDHF and NO mediate the 
vasodilator response to ACh in the rat MVB. Pretreatment with indomethacin, 
however, did not have a significant effect on the ACh-induced vasodilatation in 
perfused MVB. This was in agreement to the previous data by several investigators 
(Makino et al., 2000; Morikawa et al., 2005). The results of the present study further 
show that there appears to be interaction, or “cross-talk”, between NO and EDHF, 
such that EDHF activity is enhanced when the NO system is blunted.  
 
Inhibition of NOS with a high concentration of L-NAME (100 μmol/L) 
decreased the potency as well as maximal vasodilator response to ACh by 3 and 1.2 
fold, respectively. The present data is different from the data reported by Makino et al. 
(2000) and Wigg et al. (2001), who demonstrated that in the mesenteric arteries the 
106
 
vasodilator response to ACh persisted in the presence of L-NAME, although there was 
a significant decrease in its potency. These observations, however, suggest that there 
is a second pathway in addition to NO-mediated vasodilatation that would account for 
ACh-induced vasodilatation. A similar NO-independent component of vasodilatation 
was observed in the human forearm (Chowienczyk et al., 1993). The L-NAME-
insensitive component has generally been attributed to the existence of an EDHF 
(Feletou and Vanhoutte, 1988), which acts by increasing membrane K+ conductance 
through KCa channels, thus inducing hyperpolarization of EC with subsequent 
relaxation of vascular smooth muscle cells. In order to assess the contribution made by 
EDHF to ACh-induced vasodilatation, KCa channels were blocked by TBA. In the 
presence of TBA, both the potency and efficacy of ACh were reduced, thereby 
implicating the involvement of KCa channels in ACh-induced vasodilatation. The 
addition of TBA along with L-NAME further reduced the potency of ACh, by 34 fold 
relative to the potency seen in the absence of TBA and L-NAME and by 11.1 fold 
relative to the potency seen in the presence of L-NAME alone, indicating that there 
are at least two mechanisms by which ACh can induce vasodilatation in rat MVB, one 
involving NO and the other involving the EDHF pathway. This contrasts with the 
findings of Garland and McPherson (1992) who concluded that the release of NO was 
not involved in ACh-induced vasodilatation in isolated small mesenteric arteries. This 
may perhaps be explained by the size of the vessels being studied as Hilgers et al. 
(2005) demonstrated that the relative contribution of the EDHF-mediated 
vasodilatation differs depending on the vessel type and size, being more important in 
smaller arteries and arterioles. Hilgers et al. (2005) mentioned a greater EDHF-
mediated vasodilatation in 4th-degree branches compared to the 1st-degree branches of 
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the mesenteric arteries. ACh was less potent as a vasodilator in the presence of TBA 
than in the presence of L-NAME alone, suggesting a greater contribution of EDHF 
than NO to ACh-induced vasodilatation in the rat mesenteric arterial bed, a conclusion 
also made by Adeagbo and Triggle (1993). Accordingly, Katakam et al. (1999) 
reported that, in the presence of L-NAME and indomethacin, ACh induced a maximal 
vasodilator response of almost 70%, suggesting the EDHF as a primary endothelium-
dependent relaxing factor in rat small mesenteric arteries.  
 
Raising extracellular K+ reduces the electrochemical gradient for K+ efflux that 
could occur through all K+ channels including KCa channels. Therefore, elevated K+ 
inhibits EDHF response, and also depolarizes the VSM cell membrane resulting in 
vasoconstriction. The substantial decrease in potency and maximal responses to ACh 
in the presence of high K+ suggests that a K+ conductance was important in mediating 
vasodilatation to ACh and confirms the previous works by others (Adeagbo and 
Triggle, 1993; Waldron and Garland, 1994; Makino et al., 2000). Although the 
potency seen for ACh in the presence of KCl is the same as that in the presence of 
TBA, the maximal response to ACh in the presence of KCl was much more reduced 
compared to that in the presence of TBA. This may be due to the fact that TBA 
inhibits KCa channels, whereas increasing intracellular K+ concentration inhibits K+ 
conductance through all types of K+ channels. Others have shown that NO itself may 
act via certain K+ channel activation (KATP channel) and hyperpolarization (Tare et al., 
1990). Therefore, our hypothesis is that in the presence of TBA, although EDHF 
response is inhibited, but NO response can, up to a great extent, compensate for the 
lack of EDHF. Similar to our study, others have shown that there is an interaction 
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between NO- and EDHF-mediated responses as EDHF-mediated vasodilatation, for 
example, is particularly apparent when NO production is blocked. However, in the 
presence of KCl, where EDHF is inhibited, NO response (up to a limited extent) can 
compensate for the lack of EDHF, since NO response is also partially inhibited due to 
the blockade of all cellular K+ channels by high extracellular K+ concentration. The 
residual response to ACh in the presence of KCl is attributed to the involvement of 
NO and PGI2, since Makino et al. (2000) have demonstrated that the vasodilator 
responses of the MVBs to ACh in the presence of high K+ were completely inhibited 
in the combined presence of NOS inhibitor (L-NAME) and COX-inhibitor 
(indomethacin).   
 
The present study also investigated the relative contribution of different 
subtypes of KCa channels as well as Kir, KATP channels, and Na+/K+-ATPase pump on 
ACh-induced vasodilatations in MVB. The results strongly suggest that the 
endothelium-derived relaxing factors released in MVB in response to ACh are 
predominantly NO and EDHF: (1) Pharmacological inhibition of SKCa by apamin 
along with non-selective inhibition of IKCa and BKCa by ChTX, caused a reduction in 
ACh-induced vasodilatation. (2) Similarly, pharmacological inhibition of SKCa by 
apamin along with a very selective inhibition of IKCa by TRAM-34 also reduced ACh-
mediated vasodilatation almost to the same extent as apamin plus ChTX. (3) ACh-
induced vasodilatation of MVB was also reduced in the presence of Ba2+ and ouabain, 
which inhibit Kir channels and Na+/K+-ATPase pump, respectively. These data are 
consistent with the involvement of EDHF in ACh-mediated vasodilatation of MVB. In 
general, EDHF-mediated responses involve an increase in the [Ca2+]i levels in ECs, 
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the opening of KCa channels of small and intermediate conductance, and 
hyperpolarization of the EC. This results in an endothelium-dependent 
hyperpolarization of the smooth muscle cells, which can be evoked by direct electrical 
coupling through myo-endothelial junctions and/or the accumulation of K+ ions in the 
intracellular space. K+ ions hyperpolarize the smooth muscle cells by activation of Kir 
channels and/or Na+/K+-ATPase pump (Wang et al., 2006). In agreement with the 
above, it has been demonstrated that, in the presence of PE, ACh evoked substantial 
concentration-dependent hyperpolarization of the smooth muscle cells in the 
mesenteric arteries of control rats (Wigg et al., 2001). It is noteworthy to mention that 
this hyperpolarization was attributed to EDHF-mediated vasodilatation, since 
hyperpolarization was not affected by using a combination of NOS-inhibitor (L-
NAME) and COX-inhibitor (indomethacin), but was abolished in the presence of a 
combination of apamin plus ChTX. However, besides the involvement of EDHF, 
inhibition of KATP channels by glibenclamide, which reduced ACh-mediated 
vasodilatation of MVB, suggested the involvement of another vasodilator mechanism 
in ACh-mediated vasodilatation, namely NO. KATP channels appeared to be involved 
in NO-dependent responses and have a very minimal role in EDHF-mediated 
vasodilatation (Katakam et al., 1999).   
 
5.1.2. Ghrelin-Evoked Vasodilatation in MVB is Mediated Solely 
through EDHF 
 GHSR-1a receptors were thought to be exclusively expressed in several nuclei 
of the brain, particularly in hypothalamus and anterior pituitary gland, and at very low 
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levels in pancreas (Katugampola and Davenport, 2003). However, recent studies have 
suggested that the GHSR-1a receptors are expressed in many tissues such as lung, 
intestine, pancreas, and adipose tissue. The presence of appreciable amounts of GHS 
binding sites and mRNA in the cardiovascular system of both animals and humans 
suggests that ghrelin may have direct cardiovascular effects through GH-independent 
mechanisms (Kojima et al., 2001; Wu et al., 2004). In healthy human volunteers and 
in patients with dilated cardiomyopathy, the intravenous administration of ghrelin 
significantly reduced peripheral vascular resistance and increased cardiac output 
without a significant change in heart rate (Nagaya et al., 2001; Nagaya and Kangawa, 
2003). In rats with heart failure and cachexia, chronic ghrelin administration improves 
left ventricular remodeling (Nagaya et al., 2001). The results of the present study 
demonstrated, for the first time, that ghrelin evokes a slow concentration-dependent 
vasodilatation (EC50 55 ± 6 pmol/L) in PE-constricted rat MVB, reaching its 
maximum effect (Emax 45 ± 5) at the concentration of 1 nmol/L. MVB, consisting of 
resistance sized arteries, roughly having an internal diameter of 400-500 μm (in larger 
1st-degree branches) and 150-200 μm (in 4th-degree branches), is an important 
regulator of vascular tone and hence blood pressure. Our study, therefore suggests that 
ghrelin could be one of the most potent vasodilators and regulators of vascular tone. In 
contrast to our data, Pemberton et al. (2004) reported that PP was slightly increased in 
a dose-dependent manner during ghrelin infusion in isolated perfused rat hearts. 
Interestingly, similar to our data, the effect was pronounced at the concentration of 1 
nmol/L, which resulted in a 44 ± 9% increase in PP compared to the vehicle group. 
Administration of 1 nmol/L ghrelin also resulted in a slow constriction of coronary 
arteries. However, the observed discrepancy could be due to the different sites of 
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ghrelin administration (MVB versus coronary arteries or isolated hearts), different 
GHSR-1a expression profiles, different GHSR subtypes, and even different ghrelin 
receptors. Bodart et al. (2002) demonstrated that the increase of the coronary PP 
induced by hexarelin (a synthetic GHS) in the perfused heart model might result from 
the direct interaction of this ligand with CD36 receptors, because the lack of this effect 
was observed in CD36 knockout mice and in genetically CD36-deficient 
spontaneously hypertensive rats.  
  
 The vasodilator responses to ghrelin observed in the present study were slow in 
onset (20-30 seconds after addition of the peptide), and took between 2-3 minutes to 
reach the plateau. This is much slower than the response times for ACh, which had an 
onset of approximately 10 seconds after addition of the agonist and took 
approximately 20 seconds to reach the plateau. In addition, MVBs perfused with 
ghrelin took more time to wash and reach their basal PP compared to those perfused 
with ACh. The slower and more sustained effects of ghrelin may suggest that in vivo, 
pulses of ghrelin could promote vasodilatation evoked by this peptide. It has been 
reported that plasma concentrations of ghrelin rise progressively during fasting and 
fall after eating (Eisenstein and Greenberg, 2003). 
 
 The vasodilator effect of ghrelin seen in our MVB preparations is a 
physiological effect, since: (1) The circulating plasma concentration of ghrelin was 
shown to be about 220 pmol/L (Kojima et al., 2001; Matsumoto et al., 2001). Our 
results demonstrated that ghrelin evokes its vasodilator effect with an EC50 of 55 ± 6 
pmol/L. However, it is noteworthy to mention that the plasma concentration of 220 
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pmol/L represents the “total ghrelin” content in plasma and it does not distinguish 
between plasma levels of ghrelin, des-acyl ghrelin, or des-Gln14 ghrelin. It has been 
reported that the acylated form of ghrelin released from the stomach could be 
deacylated in the circulation (Kojima et al., 2001). Des-Gln14 ghrelin is also a form of 
ghrelin with 27 amino acids resulting from alternative splicing of the same ghrelin 
gene (Hosoda et al., 2000). (2) Ghrelin-evoked vasodilatation of MVB was 
endothelium-dependent, since the responses were not seen in endothelium-denuded 
preparations. Bedendi et al. (2003) also reported that the negative ionotropic effect of 
ghrelin on contractility of the guinea pig papillary muscles was not observed when the 
endocardial endothelium was removed. In contrast to our data, however, Wiley and 
Davenport (2002) described ghrelin as a potent endothelium-independent vasodilator 
of human internal mammary arteries, effectively reversing ET-1-mediated 
constrictions in vitro. It is noteworthy to mention that Wiley and Davenport (2002) 
employed ghrelin in vitro at doses up to 300 nmol/L, nearly 300 times those employed 
in our study. Our study demonstrated that ghrelin at concentrations more than 1 
nmol/L desensitizes its receptors, and therefore its vasodilator effect could not be 
reproduced. On the other hand, it is well known that ghrelin is a peptide, which 
promotes Ca2+ mobilization upon binding to its G protein-coupled receptors (Kojima 
et al., 1999; Kojima et al., 2001). Accordingly, previous unpublished data from our 
laboratory revealed that ghrelin evokes increases in [Ca2+]i in EC in a dose-dependent 
manner. Increases in [Ca2+]i in EC were attenuated by the IP3 (inositol-triphosphate) 
antagonist, suggesting Ca2+ mobilization from intracellular stores. Thus, the in vitro 
study by Wiley and Davenport (2002) failed to explain how a Ca2+ mobilizing agonist, 
ghrelin, could promote vasodilatation in endothelium-denuded arteries. 
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 Several lines of evidence (present study as well as previous data by our own 
laboratory and others), confirm that ghrelin-evoked vasodilatation is linked to 
endothelium-dependent hyperpolarization and EDHF: (1) Endothelium-denudation 
abolished the responses to ghrelin. (2) Inclusion of either NOSI (L-NAME) or COX 
inhibitor (indomethacin) failed to block the vasodilator responses to ghrelin in 
endothelium-intact preparations. (3) The KATP channel blocker, glibenclamide, failed 
to inhibit the responses. (4) The response to ghrelin was completely abolished in the 
presence of a non-selective KCa blocker (TBA), or in the presence of a depolarizing 
medium (KCl). (5) Inclusion of a combination of either a selective inhibitor of SKCa 
channels (apamin) and a non-selective inhibitor of BKCa and IKCa (ChTX), or apamin 
and a selective inhibitor of IKCa (TRAM-34) abolished ghrelin-evoked vasodilator 
responses. 6) Inclusion of a combination of Na+/K+-ATPase inhibitor (ouabain) and 
Kir channel blocker (Ba2+) also abolished the responses. (7) In addition to the above, 
previous data from our laboratory demonstrated that ghrelin evoked dose-dependent 
increases in [Ca2+]i, with an Emax value of 150 ± 16 nmol/L, which was significantly 
lower than the Emax for ACh (640 ± 32 nmol/L). This suggests that a higher level of 
[Ca2+]i increase is essential for the Ca2+-dependent increases in eNOS activity evoked 
by agonists like ACh. In addition, this may also explain why ghrelin fails to evoke 
NO-dependent vasodilator responses in MVB. It is noteworthy to mention that ghrelin 
reached its maximal increase in [Ca2+]i at the concentration of 1 nmol/l, the same 
concentration at which ghrelin produced its maximal vasodilator response. (8) Using 
electrophysiological studies, previous data from our laboratory also showed that 
ghrelin-evoked increases in KCa currents could induce hyperpolarization in EC 
isolated from the rat mesenteric artery (which express only IKCa channels). 
114
 
   EDHF-mediated responses have been demonstrated to be more prominent as 
the vessel size decreases, from the 1st-degree branch to the 4th-degree branch 
mesenteric arteriole rings. Hilgers et al. (2006) demonstrated that apamin almost 
completely abolished ACh-evoked vasodilatation in 4th-degree branch mesenteric 
arterioles, but only partially blocked vasodilatation in 1st-degree branch arteries. In 
addition, TRAM-34 caused significantly greater inhibition of the ACh-induced 
vasodilatation in 4th-degree branch compared to 1st-degree branch mesenteric arteries. 
Their data demonstrated regional heterogeneity in SKCa and IKCa functional gene 
expression, with the observation that relative mRNA expression levels of SKCa were 
significantly higher in 4th-degree branch compared to 1st-degree branch mesenteric 
rings. These data suggest that the observed vasodilator effect of ghrelin and des-acyl 
ghrelin arise mostly from the secondary and tertiary branches of the perfused MVB.  
 
 The present work, therefore supports the view that ghrelin increases K+ levels 
in myo-endothelial junction subsequent to the activation of SKCa and IKCa currents and 
EC hyperpolarization. The elevated K+ concentration in myo-endothelial junction, 
then hyperpolarizes underlying smooth muscle cells via activating the influx of K+ 
through Na+/K+-ATPase pump along with the efflux of the entered  K+  through the kir 
channels. Although ghrelin appears to be an agonist that selectively promotes EDHF 
process or mimickes EDHF, there is no direct evidence for ghrelin-evoked release of 
EDHF in the present study. This could be very difficult to determine, since various 
candidates have been suggested to serve the role of EDHF such as EETs, anandamide, 
hydrogen peroxide, C-type natriuretic peptide (NP), and elevation in K+ levels in the 
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myo-endothelial junctions (Edwards et al., 1998; Busse et al., 2002; Mcguire et al., 
2002; Chauhan et al., 2003). 
 
5.2. Ghrelin-Evoked Vasodilatation in MVB is not Mediated through 
the Classical GHSR-1a Receptors. 
 The results of the present study support the notion that ghrelin evokes its 
vasodilator activity in MVB through binding to a specific receptor. These include: (1) 
Ghrelin evoked slow vasodilator responses in MVB in a dose-dependent manner, 
starting at concentrations as low as 1 pmol/L (indicating specificity and selectivity). 
(2) The vasodilator response evoked by ghrelin reached its peak effect at a 
concentration range of 1 nmol/L (indicating saturability). (3) Ghrelin-evoked 
vasodilatation could be reproduced as long as the concentration of the peptide in the 
perfusion buffer did not exceed 1nmol/L (indicating reproducibility and 
desensitization). The expected ghrelin receptor seems to be present on the 
endothelium, since ghrelin-evoked vasodilator responses in MVB were abolished 
completely following endothelium removal. Kojima et al. (1999) and Katugampola et 
al. (2001) identified the presence of GHSR-1a receptor in cardiac EC. Baldanzi et al. 
(2002) also demonstrated the presence of ghrelin binding sites in membrane fractions 
of cultured porcine aortic EC. Accordingly, previous work (unpublished) by our 
laboratory identified the presence of much higher affinity sites (Kd 0.256 nmol/L) for 
[125I] ghrelin in cultured EC from the mesenteric artery compared to the affinity sites 
(Kd 8 nmol/L) for ghrelin in cultured porcine aortic EC reported by Baldanzi et al. 
(2002). In support of this data, the presence of only a single class of ghrelin binding 
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sites with similar Kd value to the data from our laboratory (0.220-0.570 nmol/L) has 
been characterized in membrane fractions of human and rat vascular tissues as well as 
human ventricle (Katugampola et al., 2001). However, despite all of the above 
information, our study can not rule out the possibility that ghrelin may also have 
receptors on the VSMC, and therefore may act directly to regulate channels (such as 
Kir channels) on VSMC. Davenport et al. (2006) reported the existence of ghrelin 
receptors on VSMC and cardiomyocytes using specific antisera.  
 
 Combining all the data together, there is a possibility for defining the presence 
of differential distribution of GHSR-1a receptors such that more receptors are present 
on EC than smooth muscle cells. Thus, in the presence of endothelium, ghrelin evokes 
its maximal vasodilator responses at the lower concentrations of about 1 nmol/L, upon 
binding to its receptors present on the EC. However, in the absence of endothelium in 
internal mammary arteries, as reported by Wiley and Davenport (2002), ghrelin 
produces its maximal vasodilator responses in the ranges up to 300 nmol/l upon 
binding to its receptors present on VSMC.  
 
 The evidence to date suggests that ghrelin is synthesized, produced, and 
released from the stomach and circulates at reasonable concentrations (220 pmol/L) to 
act on the pituitary promoting GH release (Kojima et al., 1999). More recently, the 
data by Hosoda et al. (2000) as well as Pemberton et al. (2004) demonstrated that 
cardiac tissue extracts also contained measurable amounts of ghrelin, with the atrium 
containing approximately twice as much as the ventricles. However, despite the 
presence of quantifiable amounts of ghrelin in cardiac tissue extracts, they could not 
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detect immunoreactive ghrelin in isolated heart perfusates, suggesting that if ghrelin 
has an endogenous role in mediating cardiac function, it might act in a 
paracrine/autocrine manner. There is also the possibility that ghrelin/des-acyl ghrelin 
are expressed in the EC to serve the role of EDHF and that the exogenous addition of 
these peptides mimics the response of these endogenous peptides/EDHF. To our 
knowledge, there is only one published study investigating the expression of ghrelin 
contents in EC. Davenport et al. (2006) demonstrated for the first time the expression 
of ghrelin in EC of human arteries and veins and in secretory vesicles of cultured EC 
using immunocytochemistry. However, the results of the present study are more in 
agreement with the hypothesis that, at least under normal conditions, ghrelin-evoked 
MVB relaxation is mediated mostly by circulating ghrelin binding to the receptors on 
the EC. This is because: (1) Ghrelin/des-acyl ghrelin produced their vasodilator 
responses with the potencies of 55 ± 6 pmol/L and 49 ± 7 pmol/L respectively, which 
are within their physiological range of plasma concentrations. (2) Ghrelin/des-acyl 
ghrelin did not produce any vasodilator responses in extremely low concentrations of 
100 fmol/L, thus putting a question mark on the possibility of the peptides regulating 
VSMC tone in a paracrine or autocrine manner.  
 
 The vasodilator responses to ghrelin and des-acyl ghrelin reported in the 
present study are likely mediated through a distinctly different receptor from the 
classical GHSR-1a receptors expressed in the anterior pituitary and hypothalamus for 
the following reasons: (1) Des-acyl ghrelin has been reported to bind very weakly or 
not at all to the classical GHSR-1a receptors, and is therefore devoid of any endocrine 
action (Bednarek et al., 2001; Kojima et al., 2001). In the present study, however, des-
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acyl ghrelin evoked endothelium-dependent/concentration-dependent vasodilatation in 
MVBs with a potency and maximal effect (EC50 49 ± 7 pmol/L; Emax 43 ± 6%) similar 
to those of ghrelin (EC50 55 ± 6 pmol/L; Emax 45 ± 5%). Both ghrelin and des-acyl 
ghrelin reached their maximal response at a concentration of 1 nmol/L. These 
observations are in agreement with the data by Bedendi et al. (2003), who reported 
that non-acylated ghrelin was also able to exert a negative ionotropic effect on the 
contractility of guinea pig papillary muscle similar to ghrelin. (2) [D-Lys3]-GHRP-6, 
an antagonist of the classical GHSR-1a receptor, failed to antagonize the vasodilator 
response to ghrelin. It per se evoked a vasodilator response in contracted MVBs. (3) 
L-756867, another peptide antagonist of the classical GHSR-1a receptor, which did 
not evoke vasodilatation in MVB by itself, did not block vasodilator responses evoked 
by ghrelin in contracted MVBs. In agreement with the above findings, previous data 
from our laboratory showed that des-acyl ghrelin was also able to evoke increases in 
[Ca2+]i in EC (Emax 162 ± 18 nmol/L; EC50 48 ± pmol/L) to almost the same extent as 
ghrelin (Emax 150 ± 16; EC50 58 ±  pmol/L). This finding was very different from 
previous studies reporting the potencies of des-acyl ghrelin (EC50 3500 nmol/L) and 
ghrelin (EC50 1.5 nmol/L) in increasing [Ca2+]i in somatotrophs upon binding to their 
classical GHSR-1a receptors (Matsumoto et al., 2001). Taken together, all of these 
data confirm that ghrelin and des-acyl ghrelin evoke their vasodilator responses in 
MVBs by interacting at the same novel receptor that is distinctly different from the 
classical GHSR-1a receptor present in the pituitary and hypothalamus.  
 
 The data reported by Baldanzi et al. (2002) support our observations. They 
have observed that H9C2 cardiomyocytes do not express GHSR-1a receptors, but have 
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high affinity binding sites, both for ghrelin and des-acyl ghrelin, the activation of 
which results in preventing cardiomyocyte apoptosis. This provides further support to 
the hypothesis that multiple ghrelin receptors exist in the cardiovascular system. 
However, whether this novel receptor is encoded by alternative splicing of GHSR-1a 
gene or by distinct gene is still unknown. The existence of GHS receptor subtypes in 
the heart has already been shown (Muccioli et al., 2002). GHSR-1b receptor, which is 
a splicing variant of the GHSR-1a, although expressed in the heart, does not appear to 
be functional (Howard et al., 1996). The study by Bodart et al. (2002) led to the 
discovery of a distinct type of binding sites in cardiac membranes from different 
mammalian species. Using N-terminal sequencing, the purified receptor was identified 
as CD36, a glycoprotein belonging to the scavenger receptor type-B family of 
proteins. This receptor is specifically expressed in adipose tissue, platelets, 
monocytes/macrophages, dendritic cells, and microvascular endothelium (Dawson et 
al., 1997).  
 
5.3. L-166446 and L-163255, two Synthetic Non-Peptide Agonists of 
GHSR-1a Receptors, Evoke Vasodilatation in MVB  
 GH secretion is well known to be regulated by GHRH and somatostatin at the 
hypothalamic level. The discovery of GH-releasing peptides or GHSs has revealed the 
existence of a third pathway for the modulation of GH release. In the late 1970s, 
Bowers et al. (1980) discovered that certain peptides from a series of synthetic opioid-
like peptides were able to release GH from isolated pituitary cells. GH-releasing 
peptide (GHRP)-6 was shown to induce GH secretion in a dose-dependent manner, 
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independent of the GHRH receptor (Holst et al., 2005). Several pharmaceutical 
companies initiated drug discovery projects based on this peptide and its putative 
receptor. A series of potent and efficient peptide as well as non-peptide analoges and 
antagonists were consequently developed (Holst et al., 2005). Several peptide and 
non-peptide compounds exhibited strong dose-dependent GH-releasing activity that 
was mediated through activation of GHSR-1a receptors in both in vitro and in vivo 
models (Moulas et al., 2002; Smith et al., 2005). 
  
 Theoretically, synthetic GHSs would influence cardiac structure and function 
via enhanced GH secretion. However, several studies have demonstrated that these 
molecules, at least the peptidyl ones, exert also direct and GH-independent cardiac 
actions: (1) Long-term treatment of GH-deficient rats with hexarelin, a hexapeptide 
member of the synthetic peptidyl GHS family, provided protective effect on hearts 
from ischemia/reperfusion damages and prevented alterations of the vascular 
endothelium-dependent relaxtant function (Bossni et al., 1998). (2) Hexarelin 
decreased peripheral resistance in rats with myocardial infarction (Tivesten et al., 
2001). (3) Hexarelin increased left ventricular ejection in patients with severe GH-
deficiency (Imazio et al., 2002). (4) Hexarelin also inhibited cell death in H9C2 
cardiomyocytes (Baldanzi et al., 2002), and (5) Hexarelin was shown to have a 
negative ionotropic effect on both rat and guinea pig papillary muscle (Bedendi et al., 
2003).  
 
 Despite a wide spectrum of cardiac and vascular actions of synthetic peptidyl 
GHSs, the effects of synthetic non-peptidyl GHSs on the cardiovascular function have 
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not been much studied. Frascarelli et al. (2003) reported that, while hexarelin 
significantly reduced infarct size in rat hearts subjected to 30 minutes of ischemia 
followed by 120 minutes of reperfusion, the synthetic non-peptidyl GHS, MK-0677, 
was ineffective. However, like hexarelin, MK-0677 was able to inhibit cell death in 
H9C2 cardiomyocytes (Baldanzi et al., 2002). Therefore, in the present study, we were 
interested to characterize the two synthetic non-peptidyl GHSs, L-166446 and L-
163255, in respect to their ability to stimulate vasodilator responses in PE-constricted 
MVB. This could have a very important advantage. For many years, investigators 
have been searching for new therapeutic molecules to treat patients with 
cardiovascular diseases such as hypertension. The oral bioavailability of the peptidyl 
GHSs is limited (Moulas et al., 2002). However, recently available non-peptide 
secretagogues have been reported to be orally active and effective. Therefore, if the 
non-peptidyl GHSs, L-166446 and L-163255, could evoke vasodilatation in PE-
constricted MVB, it could be investigated for potential use in the management of 
cardiovascular disease states. However, it should be noted that synthetic GHS 
compounds have been found to have different molecular pharmacological properties 
on their own as agonists. That is, the non-endogenous ghrelin receptor agonists can act 
both as positive as well as negative allosteric modulators of ghrelin signaling (Holst et 
al., 2005). It is, therefore, proposed that compounds, which act both as agonists and as 
positive allosteric modulators of the signaling of the endogenous ligand ghrelin could 
be the optimal type of compound that could be considered for use in clinical settings.  
  
 Very interestingly, the results of the present study clearly demonstrate that the 
synthetic non-peptidyl GHSs, L-166446 and L-163255, evoke concentration-
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dependent vasodilatation in PE-constricted MVB. As mentioned earlier, similar to 
ghrelin, synthetic peptidyl and non-peptidyl GHSs were shown to release GH through 
binding to their GHSR-1a receptors. Our results suggest the involvement of a different 
class of GHS receptors than GHSR-1a in vasodilator responses evoked by synthetic 
non-peptides, because both non-peptidyl GHSs, L-166446 (EC50 4 ± 2 pmol/L) and L-
163255 (EC50 6 ± 3 pmol/L), were very potent in inducing their vasodilator responses 
in MVB. Both L-166446 and L-163255 evoked their vasodilator responses in the same 
concentration range as ghrelin and des-acyl ghrelin, with a threshold concentration at 
1-10 pmol/L reaching a maximal effect at concentrations of about 1 nmol/L. Similar to 
ghrelin and des-acyl ghrelin, the non-peptides were also slow in evoking their dilator 
responses. However, both L-166446 (EC50 4 ± 2 pmol/L; Emax 70 ± 6%) and L-163255 
(EC50 6 ± 3 pmol/L; Emax 60 ± 7%) are more potent than ghrelin (EC50 55 ± 6 pmol/L; 
Emax 45 ± 5%) and des-acyl ghrelin (EC50 49 ± 7 pmol/L; Emax 43 ± 6%) in evoking 
their vasodilator responses in MVB. Previous studies have demonstrated the existence 
of a receptor in cultured cardiomyocytes and endothelial cells that binds hexarelin, as 
well as ghrelin either in acylated or unacylated form (Baldanzi et al., 2002; Bedendi et 
al., 2003). On the other hand, some others have reported that, besides GHSR-1a 
receptor, there are other specific binding sites labeled by [125I] His9-ghrelin in animal 
and human myocardium that are specific for peptidyl GHSs and that these binding 
sites do not recognize the non-peptidyl GHS, MK-0677 (Bodart et al., 1993; Papotti et 
al., 2000). These suggest the hypothesis that, from multiple ghrelin and GHS receptors 
identified in the cardiovascular system, each receptor may then contribute 
independently to the wide array of cardiovascular activities induced by synthetic 
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peptidyl GHSs, synthetic nonpeptidyl GHSs, ghrelin, and endogenous ghrelin-derived 
molecules. 
 
5.4. Active Core of Ghrelin, Necessary for its Vasodilator Activity, 
Consists of an N-terminal three Amino Acid Segment Without n-
octanoyl Modification 
 The results of the present study clearly demonstrate that the n-octanoyl 
modification at the hydroxyl group of the Ser3 residue of 28-amino acid ghrelin is not 
necessary for induction of its vasodilator activity, because des-acyl ghrelin evoked 
concentration-dependent vasodilator responses similar to ghrelin. This was 
understandable, since to date no octanoyl modifications have been considered to be a 
prerequisit for bioactive peptides and proteins in the mammalian system. It is 
noteworthy to mention that our present finding was in contrast to the previous studies 
reporting the essentiality of n-octanoyl modification for ghrelin binding to its receptor 
GHSR-1a, and therefore the release of GH (Kojima et al., 1999). However, the 
identity of the portions of the des-acyl ghrelin peptide necessary for its vasodilator 
activity remains unknown. To address this issue, several des-acyl fragments with 
varying lengths were prepared by successive deletions of amino acids from the C-
terminal while the N-terminal end was kept intact. This is because of the previous 
observations that 10 N-terminal amino acids of ghrelin are identical among the 
different mammalian species. The C-terminal portions of ghrelin, however, are varied, 
suggesting that the N-terminal portion of ghrelin contains the active core (Matsumoto 
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et al., 2001). Moreover, Matsumoto et al. (2001) demonstrated that the C-terminal 
fragment of ghrelin, ghrelin [16-28], was completely inactive.  
 
 The evaluation of the vasodilator activity of the prepared short peptide 
fragments of des-acyl ghrelin demonstrated for the first time that all short peptide 
fragments of des-acyl ghrelin (des[1-20], des[1-16], des[1-10], des[1-6], des[1-4], 
des[1-3]) up to three amino acid length evoked vasodilator responses with an efficacy 
similar to that of full-length des-acyl ghrelin. Previous studies by Bednarek et al. 
(2000) and Matsumoto et al. (2001), however, indicated that successive deletions of 
the C-terminal amino acids of ghrelin led to successive decreases in the potency of the 
peptides to elevate [Ca2+]i. They have also reported that when the peptide length was 
shortened to a tri-peptide, no activity was observed, even in the presence of the 
octanoyl modification. Their results demonstrated that the minimum core of ghrelin 
mediating GHSR-1a GH stimulating activity resides in the N-terminal tetra-peptide, 
absolutely requiring the octanoyl group at the third residue. This is in comparison to 
our study identifying the minimum active core of ghrelin as the N-terminal tri-peptide 
without the octanoyl modification at the third serine residue, or the three-amino acid 
sequence of des-acyl ghrelin from the N-terminal. The difference between our results 
and the results from the previous studies can be explained as follows: Ghrelin/Des-
acyl ghrelin-evoked vasodilator responses are mediated through a different class of 
receptors distinctly different from the classical GHSR-1a receptors involved in GH-
releasing activity. 
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 The present study also discovered that even single amino acids such as L-
serine and glycine can induce vasodilator responses in MVB. These effects do not 
seem to be artifacts, as maximal vasodilator responses evoked by single amino acids 
were significantly reduced compared to ghrelin/des-acyl ghrelin. The vasodilator 
responses evoked by glycine were very negligible compared to those evoked by L-
serine. Single amino acids produced their dilator effects at the concentration of 1 
nmol/L. Involvement of amino acids in the cardiovascular function has been 
mentioned for a long time. L-arginine, for example, is a precursor amino acid for the 
synthesis of NO by NOS. NO accounts for a major portion of the endothelium-
dependent vasodilatation produced in a variety of blood vessels. Therefore, a defect in 
the L-arginine supply may produce inadequate levels of NO, and thus impaired 
endothelium-dependent vasodilatation (Pieper and Dondlinger, 1997). In addition to 
L-arginine, animal and human studies have shown a homocysteine-lowering effect of 
serine treatment (Verhoef et al., 2004). Increased homocysteine is usually associated 
with the cardiovascular disease.  
 
 Besides vasodilator responses evoked by single amino acids observed in the 
present study, it is noteworthy to mention that if single amino acids could provoke 
hypotensive effects in the whole animal, it could be a major finding towards new 
therapeutic agents for the treatment of hypertension. Amino acid therapy with L-serine 
and glycine in patients with congenital microcephaly and seizures has been reported to 
be well tolerated, beneficial, and without side effects (Koning et al., 2002; Asechi et 
al., 2006).  
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5.5. Diabetes Mellitus Type 1 
5.5.1. Plasma Ghrelin Concentrations Are Markedly Elevated in 
STZ-Treated Diabetic Rats 
In agreement with the previous data, our experiments demonstrated that fasting 
led to a significant increase in plasma total ghrelin levels in both control and diabetic 
rats. A significant increase in plasma ghrelin levels also occurred in a progressive 
duration-dependent manner in STZ-diabetic rats. Increased plasma ghrelin levels in 
STZ-diabetic rats may be due to an increase in ghrelin synthesis and release by the 
stomach into the blood stream. Increased plasma ghrelin levels in STZ-diabetes 
coincides with the decreased gastric ghrelin levels (Masaoka et al., 2003). The number 
of ghrelin-immunoreactive cells in the gastric fundus of diabetic rats was also decreased 
significantly compared to control rats. Increased plasma ghrelin levels can not be due to 
a direct irreversible toxicity of STZ on the gastric mucosa and a simultaneous release of 
the cell contents, since plasma ghrelin concentrations were shown to be quickly 
normalized by insulin treatment in the STZ-diabetic rats (Ishii et al., 2002; Masaoka et 
al., 2003). Although the changes in plasma ghrelin concentrations in fasting and diabetes 
compared to respective control groups are consistent with the data in the literature, there 
is a substantial degree of variability amongst these observations. There are a few 
possibilities that may account for the variations including: (1) Duration of the fasting 
time in both animals and humans. To our knowledge, there is no study reporting the 
effect of different fasting times on plasma ghrelin levels. However, in the study done by 
Tschop et al. (2000), where very high basal and fasting plasma ghrelin levels were 
reported, the animals were fasted for 48 hr compared to the overnight fasting state 
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maintained in our experiments. A comparison of fasting plasma ghrelin levels between 
47 individuals with chronic alcoholism during a period of abstinence and 50 control 
subjects, observed a positive correlation between ghrelin levels and the duration of 
abstinence. (2) Animal species, strains, and categories of human subjects. It is possible 
that rodents may not be ideal for these types of studies. Rats, for example, appeare to 
exhibit a paradoxical fall in GH levels with hypoglycemia (Flanagan et al., 2003). (3) 
Animal sex and human gender. Our experiments were performed using male rats. 
However, there are some studies showing the existence of sexual dimorphism for 
ghrelin. Plasma ghrelin levels were significantly higher in female than in male infants 
(Ng et al., 2004). Similar observations were reported in adult human subjects under fed 
as well as fasting states (Greeman et al., 2004). (4) Age of animals and human subjects. 
Plasma ghrelin levels were found to be inversely correlated with age (Haqq et al., 2003). 
There was no signs of difference in plasma ghrelin levels in our control group of rats 
between the age of 16 (4-weeks control) to 20 weeks (8-weeks control).  In contrast, 
plasma ghrelin levels were significantly higher in 8-weeks STZ-treated rats compated to 
4-weeks STZ-diabetic rats.  
  
Increased plasma ghrelin levels may be beneficial in diabetes, as ghrelin has been 
shown to serve as a physiological regulator of insulin release (Date et al., 2002). Both 
ghrelin and its receptors are present in the pancreatic islets (Date et al., 2002). 
Additionally, it was also demonstrated that glucose-stimulated insulin release was 
significantly increased by the addition of 1 pmol/l ghrelin, and ghrelin at the same 
concentration increased [Ca 2+]i in single rat pancreatic β cells (Date et al., 2002). This 
128
 
effect of ghrelin, however, may not be important in our STZ-induced diabetic rats, a type 
I diabetic rat model. This may have a more beneficiary effect in type II diabetes, where 
the cells develop a resistant state to insulin. Contradictory to the proposed hypothesis, 
however, previous data have demonstrated that plasma ghrelin levels are decreased in 
type II diabetes (Poykko et al., 2003). Moreover, as an orexigenic peptide, ghrelin 
promotes increases in plasma concentration of glucose, and thus may affect glucose 
homeostasis in different levels, which may be harmfull in type II diabetes.  
  
The mechanisms by which plasma ghrelin concentrations are elevated in STZ-
induced diabetes are largely unknown. Reduced plasma GH levels could be a possible 
mechanism. Tschop et al. (2002) demonstrated that circulating levels of endogenous 
ghrelin were reduced by the administration of GH in normal rats, and were markedly 
increased in hypophysectomized rats. Reduced plasma leptin levels were also shown to 
increase the concentration of ghrelin. The gastric ghrelin mRNA expression was 
elevated in ob/ob mice, which are deficient in leptin and thereby manifest hyperphagia 
and obesity (Lee et al., 2002). Additionally, in rodents, fasting and hypoglycemia 
increase both ghrelin mRNA levels and plasma concentrations, whereas enhanced food 
intake and elevated plasma glucose decrease ghrelin secretion (Lee et al., 2002). 
Furthermore, plasma ghrelin concentrations of normal human subjects decrease 
significantly after oral or intravenous glucose administration (Shiiya et al., 2002). In 
contrast, the reports on the effects of insulin on ghrelin synthesis or release are 
conflicting. Insulin treatment increased or did not affect the expression of the ghrelin 
gene in the stomach of rodents and humans (Toshina et al., 2001; Caixas et al., 2002; 
Shiiya et al., 2002). Gelling et al. (2004) drew some important conclusions. They 
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demonstrated that meal-induced suppression of plasma ghrelin is intact in STZ rats, and 
that this response occurs despite the absence of any postprandial increase in plasma 
insulin levels. This provides unequivocal evidence that meal-related increases in insulin 
are not required for acute nutrient-induced lowering of circulating ghrelin. However, 
meal-induced suppression of plasma ghrelin levels was relatively short-lived in STZ 
rats, suggesting that the inhibitory effects of postprandial insulin release are a key 
determinant of the duration of meal-induced inhibition of ghrelin release, and thus the 
time course over which plasma levels of ghrelin are restored to pre-prandial values. This 
interpretation is compatible with findings from studies in humans with type I diabetes 
suggesting that insulin has a physiological inhibitory role, and is a determinant of the 
duration of meal-induced ghrelin suppression (Spranger et al., 2003).  
  
In agreement with previous data suggesting an inhibitory role of insulin on 
plasma ghrelin levels, increased plasma ghrelin levels in our STZ-treated diabetic rats 
were in the presence of decreased insulin concentrations. However, our diabetic data still 
leaves the question of “whether or not insulin plays an inhibitory role on ghrelin 
secretion?” unanswered, as we did not measure plasma insulin and ghrelin contents over 
a certain period of time. STZ injection is shown to cause a marked decrease in plasma 
insulin concentrations. Gelling et al. (2004) also demonstrated that within one day of 
STZ injection, plasma insulin levels drop more than half compared to the control 
situation. This effect was accompanied by elevated glucose within one day. However, 
they demonstrated that food intake decreased initially up to two days and the onset of 
hyperphagia was not evident until day three after STZ administration. Therefore, 
according to the above explanation and our finding of increased plasma ghrelin levels in 
130
 
diabetes, we hypothesize that very early (up to three days) after STZ injection, insulin 
deficiency stimulates ghrelin secretion and raises its plasma concentrations to a very 
high level, when the hyperphagia is not yet started and blood glucose levels still are not 
that high to inhibit ghrelin secretion. But, as the food intake increases and blood glucose 
levels start to increase more and sustain in that elevated level, nutrient-induced 
inhibition of ghrelin secretion partially offsets the stimulatory effect of uncontrolled 
diabetes and lower plasma levels of this hormone. Finally, the two opposing effects of 
insulin deficiency in uncontrolled STZ-diabetes and high blood glucose levels result in 
the steady-state values of plasma ghrelin that are still markedly higher than in non-
diabetic animals, but are constrained by hyperphagic feeding. This proposed hypothesis, 
however, needs further investigation.  
 
5.5.2. Ghrelin- and ACh-Evoked Vasodilatations in MVB are 
Diminished in STZ-treated Diabetic Rats.  
 As mentioned earlier, the results of the present study clearly demonstrate that 
ghrelin is a potent vasodilator agonist in the MVB. This was confirmed in our control 
fed rats, where ghrelin relaxed MVB by 40-45% compared to 98% vasodilatation 
evoked by ACh. However, the vasodilator effect of ghrelin in MVB has never been 
studied in diabetes mellitus. Relating plasma ghrelin levels with its vasodilator action in 
MVB, our present study for the first time shows that despite increased plasma ghrelin 
levels, its vasodilator effect was significantly reduced in later stages (8-weeks) of STZ-
induced diabetes. The vasodilator effect of ghrelin, however, was preserved in earlier 
stages (4-weeks) of STZ-induced diabetes, when plasma ghrelin levels were still very 
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high. In comparison to what was observed for ghrelin, vasodilator response to ACh was 
decreased gradually with the progression of the disease.  
  
Decrease in endothelium-dependent vasodilatation has been demonstrated as a 
common feature in both conduit and resistance arteries of not only chemically-induced 
experimental diabetic animals, but also in genetic models of insulin-dependent diabetes 
mellitus (IDDM) as well as in patients with type I diabetes (Pieper, 1998). In perfused 
MVB pre-constricted with PE, infusion of cumulative concentrations of ACh causes 
concentration-dependent vasodilatation. In agreement with our data, an accumulating 
body of evidence shows that the vasodilatation induced by ACh (in both conduit and 
resistance arteries) is attenuated in STZ-diabetic rats (Hopfener et al., 1999; Makino et 
al., 2000). However, the degree of attenuation reported by various studies differs 
considerably. Endothelium-dependent vasodilatation to ACh in aortic rings was 
attenuated in 14-week, by approximately 30%, but not in 2-week diabetic rats (Hopfner 
et al., 1999). In comparison, our results demonstrated more than 30% decrease in 
vasodilatation to ACh in MVB after 8 weeks of diabetes. It is important to note that the 
onset and degree of endothelial dysfunction may vary widely among individual vascular 
beds. In addition, the duration, and /or the severity of the diabetic model used in any 
given study are also different. 
  
ACh has been known for a long time to promote vasodilatation of blood vessels 
via the release of multiple vasodilator substances, EDRF, now identified as NO, PGI2, 
and EDHF (Furchgott and Zawadzki, 1980; Palmer et al., 1987; Garland et al., 1995). 
The component of EDHF versus NO, however, increases with decreasing vessel size. 
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Whereas NO is the major vasodilator factor in aorta, EDHF has been mentioned as the 
primary endothelium-mediated relaxing factor in small mesenteric arteries (Katakam et 
al., 1999).  
 
 Several studies support the concept that insulin-dependent diabetes mellitus 
decreases NO production and bioactivity (Pieper, 1998). The ability of NO inhibition to 
attenuate ACh-induced vasodilatation was reduced in the 14-week STZ rats relative to 
the 2-week STZ-treated rats (Misurski and Gopalakrishnan, 2002). Glucose possesses a 
reactive aldehyde moiety that reacts non-enzymatically with the amino groups of 
proteins, forming products, termed advanced glycation end-products (AGEs), which 
remain irreversibly bound to proteins (Bucala and Cerami, 1992). It is noteworthy to 
mention that AGE modification occurs not only to proteins, but also to DNA and lipids 
and particularly to components of connective tissue. It is hypothesized that AGE 
modification of proteins and the AGE binding to its receptors on EC, induce drastic 
alterations in many endothelial functions, representing a critical and initiating factor in 
the development of diabetic vascular disease (Rojas et al., 2004). AGEs are known to 
quench NO (Rojas et al., 2004). In addition, studies have also shown a marked reduction 
in protein and gene expression of endothelial NOS, by decreasing serine 
phosphorylation of this enzyme and increasing the rate of mRNA degradation, when EC 
were cultured in the presence of AGEs (Xu et al., 2003; Rojas et al., 2004). Very 
interestingly, increased serum concentrations of AGEs in patients with type II diabetes 
are associated with higher magnitude of endothelial dysfunction (Tan et al., 2002). 
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Endothelium dysfunction, and thus impaired vasodilatation, was shown to arise 
from deficits in EDHF in certain blood vessel types. A study by Fukao et al. (1997) 
demonstrated that while resting membrane potential was normal, the response of the 
diabetic mesenteric artery to ACh was accompanied by diminished hyperpolarization 
despite unaltered hyperpolarization in response to the K+ channel agonist, pinacidil. This 
study was conducted in the presence of NOS and COX inhibitors, suggesting that the 
release or synthesis of EDHF in the diabetic state may be reduced by comparison with 
that in the controls. Involvement of a defective EDHF pathway in an impaired 
endothelium-dependent vasodilatation of mesenteric arterial bed to ACh in STZ-induced 
diabetic rats was also seen by Makino et al. (2000). They further suggested that the 
elevated K+ levels in the myo-endothelial space serves as EDHF and that the 
vasodilatation response to K+ is impaired in the MVB from diabetic rats. However, in the 
latter study, pretreatment with indomethacin had no effect on the ACh-induced dose-
dependent vasodilatation in either control or diabetic rats, suggesting that prostanoids 
are not involved in the ACh-induced vasodilatation in MVB. EDHF-mediated 
vasodilatation was also shown severely compromised in mesenteric arteries from 
insulin-resistant rats fed a fructose-rich diet for seven days (Katakam et al., 1999).  
  
Many studies have demonstrated a marked increase in plasma low density 
lipoproteins (LDL) in the diabetic state, indicating that the impairment of the EDHF-
mediated response may be, at least in part, due to the increase in plasma LDL (Katakam 
et al., 1999; Kobayashi and Kamata, 1999). Indeed, one possible explanation for the 
decreased EDHF-mediated vasodilatation could be attributed to the following sequence 
of events: STZ-diabetes leads to an increase in plasma LDL cholesterol and a decrease 
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in superoxide dismutase levels in blood vessels (Katakam et al., 1999; Kobayashi and 
Kamata, 1999). The decreased superoxide dismutase activity causes an increased 
accumulation of superoxide anions. The accumulated superoxide anions may oxidize 
LDL (Kobayashi and Kamata, 1999). The oxidized LDL may itself impair the EDHF-
mediated response and/or the oxidized LDL may release lysophosphatidylcholine (LPC), 
which then attenuates the EDHF-mediated hyperpolarization (Fukao et al., 1995). The 
oxidized LDL or LPC may also inhibit Ca2+ influx into the endothelium, thus reducing 
the production or release of EDHF, since this requires an increase in [Ca2+]i in the 
endothelium (Chen and Suzuki, 1990; Kamata and Nakajima, 1998). As a result, ACh-
induced vasodilatation in the presence of NOS inhibitors would be significantly 
impaired in the MVBs from diabetic rats. 
  
Several explanations could be proposed in support of our observation of 
decreased ghrelin-evoked vasodilatation in MVB in the later stages of diabetes. Firstly, 
there may be a deficit in the mechanism by which ghrelin evokes vasodilatation in 
MVB. In vivo and in vitro studies on the cardiovascular actions of ghrelin have not 
explored the exact mechanism(s) involved. However, previous data from our own 
laboratory showed that the hypotensive effect of ghrelin is endothelium-dependent, but 
NO- and COX-independent (Shinde et al., 2005). This is because pretreatment with 
indomethacin and L-NAME, either alone or in combination, failed to attenuate the fall in 
MAP evoked by ghrelin. This is in accordance with the data presented by other 
investigators who showed that intra-arterial vasodilatation produced by the infusion of 
ghrelin in human forearm was NO-independent (Okumura et al., 2002). Interestingly, a 
single bolus administration of ghrelin in TBA-pretreated rats failed to induce a fall in 
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MAP. These data confirm that the acute hypotensive and vasodilator responses to 
ghrelin are due to the activation of vascular KCa channels, that are sensitive to blockade 
by TBA and promoting the generation of endothelium-dependent hyperpolarization. 
This is consistent with the observation that the synthetic GHS ligand, hexarelin, evoked 
K+ conductance in pituitary somatotrophs (Herrington and Hille, 1994). Following these 
observations, previous data from our laboratory showed that in adherent EC, the addition 
of ghrelin evoked rapid concentration-dependent increases in [Ca2+]i. Ca2+ mobilization 
following ghrelin binding to the GHS-R type-1a receptors in somatotrophs of pituitary 
was also observed (Kojima et al., 1999). Ghrelin, therefore, appears to be an agonist that 
selectively promotes EDHF process or mimics EDHF, since it seems to fulfill all the 
criteria defining EDHF or the mechanism of endothelium-dependent hyperpolarization. 
  
Considering all the above information, the acute hypotensive effect of ghrelin in 
MVB is EDHF-mediated, and that diabetes impairs the EDHF-mediated vasodilatation, 
making it possible to conclude that the decrease in ghrelin-evoked vasodilatation in the 
later stages of diabetes in MVB may in part be due to an impaired EDHF release. The 
possibilities of an impaired production of EDHF or an enhanced breakdown of EDHF 
are likely. The EDHF pathway, however, seems to be normal at the earlier stages of 
diabetes, as ghrelin-evoked vasodilatation of MVB was preserved in 4-week diabetic 
rats.  
  
Reduced ghrelin-evoked vasodilatation in later stages of diabetes could also be 
attributed to the decrease in the number of ghrelin receptors or to the receptor 
desensitization, since an increase in the plasma ghrelin concentration could theoretically 
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lead to a down-regulation of ghrelin receptors. It is also noteworthy to mention that 
plasma glucose levels may also have some regulatory effect on the number and also the 
function of ghrelin receptors, since plasma glucose levels are highly elevated in IDDM, 
and glucose administration has been associated with changes in plasma ghrelin content. 
Hyperglycemia has been shown to cause hyperactivity of isoforms of protein kinase C 
(PKC) (Rojas et al., 2004). Hyperglycemia-mediated PKC activation has been 
demonstrated to selectively regulate the receptors for, and responses to, ET-1 (Xu et al., 
1993). 
  
In conclusion, our results demonstrate that despite increased plasma ghrelin 
levels in both early and later stages of diabetes, the ghrelin vasodilator effect is 
preserved in the early diabetic stage and vasodilatation to ghrelin is impaired only in the 
later stages of diabetes. These changes were concomitant with the observation that ACh-
induced relaxation of MVB is progressively diminished from early to the later stages of 
diabetes. Ghrelin-evoked vasodilatation, which is supposed to be mediated through the 
EDHF pathway, seems to be intact in the early diabetes, when the NO pathway is 
progressively impaired. This is consistent with the observation that NO inhibits EDHF 
activity such that EDHF may act as a primary endothelium-dependent relaxing factor 
only when NO is diminished. Our results suggest that, in early diabetes, when NO-
mediated vasodilatation begins to deteriorate, the alternative compensatory vasodilatator 
pathway by EDHF may be activated, which could mask impaired NO-induced 
endothelium-dependent vasodilatation to compensate for defective NO synthesis. Our 
present observation that ghrelin-evoked vasodilatation is preserved in early stage of 
STZ-induced diabetes, while NO is deteriorated, may contribute to increased capillary 
137
 
perfusion observed in early type I diabetes. Additionally, the diminished ghrelin-evoked 
vasodilatation in conjunction with a more attenuated NO pathway in chronic diabetes 
may contribute to the hypertensive and atherosclerotic changes observed in the late 
stages of the disease. 
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6. Summary 
 The ability of ghrelin and des-acyl ghrelin to produce vasodilator responses in 
MVB was investigated in the presence and absence of endothelium in 12 week old male 
SD rats. We first examined agonist-evoked vasodilator responses to ACh, and then 
compared the results to those evoked by ghrelin and des-acyl ghrelin. In endothelium-
intact PE-constricted preparations, increasing concentrations of ghrelin, des-acyl ghrelin, 
and ACh produced concentration-dependent vasodilator responses. However, we found 
that ghrelin and des-acyl ghrelin were much more potent, with lower maximal 
vasodilator responses, compared to ACh. Similar to ACh, endothelium-removal 
completely abolished vasodilator responses to increasing concentrations of ghrelin and 
des-acyl ghrelin. Agonist-evoked vasodilator responses to SNP, an NO donor, were 
unaffected in both endothelium-intact as well as endothelium-denuded preparations.  
 
 Having established the vasodilator effect of des-acyl ghrelin to the same extent 
as ghrelin, our data revealed that the whole molecule of ghrelin may not be necessary for 
its vasodilator response. To determine the active core required for des-acyl ghrelin-
evoked vasodilatation, vasodilator responses to several fragments of des-acyl ghrelin, 
prepared by successive deletions of the C-terminal amino acid residues, were evaluated. 
We found that all short peptides encompassing the first 20, 16, 10, 6, 4, and 3 residues of 
des-acyl ghrelin were able to evoke vasodilator responses to the same extent as the full-
length des-acyl ghrelin. Vasodilator responses to single amino acids L-serine or glycine, 
however, were significantly attenuated. 
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 In terms of understanding the underlying mechanism(s) of agonist-evoked 
vasodilatation to both ghrelin and ACh, several experiments were performed to 
determine the relative contributions of distinct mediators of endothelium-dependent 
vasodilator responses including NO, EDHF, and PGI2. While inclusion of a high 
concentration of L-NAME failed to affect vasodilator responses to increasing 
concentrations of ghrelin, there was a significant rightward shift in the CR curve, 
accompanied by a significant reduction in Emax, to ACh. Ghrelin-induced vasodilatation 
was completely abolished in the presence of TBA, and a combination of TBA and L-
NAME did not affect the response any further. In contrast, vasodilator responses to ACh 
were significantly shifted to the right with a significant reduction in maximal 
vasodilatation in the presence of TBA. Vasodilator response to ACh was even further 
attenuated in the presence of a combination of TBA and L-NAME. Increasing ghrelin 
concentrations failed to evoke vasodilator responses in the presence of high K+-
containing depolarizing buffer. The ACh-evoked vasodilatations were also significantly 
lower in the presence of high K+-containing buffer compared to the response seen in PE-
constricted MVB preparations. The functional importance of SKCa and IKCa channels in 
the maximal vasodilatations evoked by ghrelin and ACh was examined in the presence 
of apamin + ChTX or apamin + TRAM-34. Maximal vasodilator responses evoked by 
both ghrelin and ACh were significantly reduced in the presence of apamin + ChTX, and 
even further reduced in the presence of apamin + TRAM-34. Treatment with ouabain 
and Ba2+ diminished ghrelin- and ACh-evoked maximal vasodilatations significantly. 
Inclusion of glibenclamide in the perfusion buffer revealed minimal involvement of 
KATP channels in vasodilator response evoked by ghrelin. However, maximal 
vasodilatation to ACh was significantly attenuated in the presence of glibenclamide. 
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 Having established the presence of GHSR-1a receptors in the cardiovascular 
system, we determined the involvement of GHSR-1a receptors in ghrelin-evoked 
vasodilatation using both antagonists as well as agonists of the classical GHSR-1a 
receptor. The addition of a high concentration of [D-Lys3]-GHRP-6, a competitive 
antagonist of the classical GHSR-1a receptor, to the perfusion buffer induced decreases 
in PP in PE-constricted MVB. Furthermore, the inclusion of L-756867, a peptide 
antagonist of the classical GHSR-1a receptor, in the perfusion buffer failed to evoke any 
vasodilator responses on its own or affect the vasodilator responses evoked by ghrelin in 
PE-constricted MVB. Both non-peptide agonists of GHSR-1a receptors, L-166446 and 
L-163255, on the other hand, demonstrated concentration-dependent decreases in PP, 
which were much more potent with significantly higher maximal vasodilatation 
compared to the response evoked by ghrelin.  
 
 Finally, the ability of diabetes to affect vasodilator responses evoked by ghrelin 
and ACh was investigated in STZ-induced diabetic rats. We first measured plasma 
ghrelin concentrations, and then evaluated agonist-evoked vasodilatation to both ghrelin 
and ACh in PE-constricted MVB of both control and STZ-induced diabetic rats. Given 
the progressive nature of the disease, we chose an early/intermediate (4 weeks) and later 
(8 weeks) stage of diabetes, in which to assess these responses. We first found that 
diabetes increases plasma ghrelin concentrations in both 4- and 8-weeks diabetic 
(fed/fasted) animals compared to their age-matched control rats. In terms of vasodilator 
responses, however, diabetes for 4 weeks did not cause any significant reduction in 
vasodilator response to ghrelin, whereas diabetes for 8 weeks induced a very significant 
reduction in ghrelin-evoked vasodilator responses. Ghrelin-induced vasodilator 
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responses in 8-weeks diabetic (fed/fasted) animals were significantly different compared 
to 4-weeks diabetic (fed/fasted) rats. In contrast to ghrelin-evoked vasodilator responses, 
our data demonstrated that there was a duration-dependent fall in the vasodilator 
responses to ACh in STZ-diabetic rats compared to their age-matched control groups. 
The ACh-evoked vasodilatations were significantly lower in 8-weeks compared to 4-
weeks STZ-diabetic rats.  
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7. Conclusions 
 The results of the present study demonstrate, for the first time, a role for ghrelin 
and des-acyl ghrelin in mediating vasodilatory effects in MVB by promoting 
endothelium-dependent hyperpolarization of VSMC and the EDHF process. These data, 
in conjunction with the previous data from our own laboratory demonstrating the KCa 
channel-mediated ghrelin-evoked decreases in MAP in anaestethized male SD rats, may 
suggest an important role for ghrelin-evoked vasodilatation, and thus decreases in MAP, 
in states of endothelial dysfunction associated with reduced NO availability such as 
diabetes and hypertension. The data presented in this thesis suggest that in 
early/intermediate stages of STZ-induced diabetes, increased plasma ghrelin levels lead 
to the decreased MVB resistance and exaggerated vasodilator response via activation of 
the EDHF process. At later stages of STZ-diabetes, the enhanced vasodilatation due to 
ghrelin is countered by the impairement of EDHF process. Diabetes mellitus is 
essentially a metabolic disorder characterized by vascular complications that result in a 
significant morbidity and mortality. Tight glycemic control is a nobel goal, but often an 
unrealistic one, given the expense and invasiveness of current methods of treatment and 
monitoring. Ghrelin, therefore, may become a powerful tool in the management of 
cardiovascular function in disease states such as diabetes and hypertension. 
 
 However, ghrelin, which is by far the most studied GHS, has a limited oral 
bioavailability. Several pharmaceutical companies initiated drug discovery projects and 
as a result a series of potent and efficient non-peptide compounds exhibiting GH-
releasing activity were developed. Recently, available non-peptide secretagogues have 
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been reported to be orally active and effective. The effects of synthetic non-peptidyl 
GHSs on the cardiovascular function have not been much studied. The results of the 
present study clearly demonstrated that both synthetic non-peptidyl GHSs, L-166446 
and L-163255, evoked concentration-dependent vasodilatation in PE-constricted MVB. 
Therefore, if the non-peptidyl GHSs, L-166446 and L-163255, could also evoke 
decreases in MAP, they could be investigated for potential use in the management of 
cardiovascular disease states. 
 
 Having established that the n-octanoyl modification at the ser3 residue of the 28-
amino acid ghrelin is not necessary for induction of its vasodilator activity, our study, 
for the first time, identified the minimum active core of des-acyl ghrelin molecule 
necessary for its vasodilator effect to be the N-terminal tri-peptide. Single amino acids, 
such as L-serine and glycine, could also induce vasodilator responses in MVB. The 
involvement of amino acids in the cardiovascular function has been mentioned for a long 
time. If single amino acids could provoke hypotensive effects in the whole animal, it 
could be a major finding towards new therapeutic agents for the treatment of 
cardiovascular disease.     
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